Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 2 PROTOCOL AMENDMENT S UMMARY OF CHANGES   
DOCUMENT HISTORY   
Document  Country/countries  
impacted by 
amendment  Date, version  
Amended Clinical Trial Protocol 03  all 25 January 2021 , Version 1 (electronic 4.0) 
Amended Clinical Trial Protocol 02  all 10 December 2020 , Version 1 (electronic  2.0) 
Amended Clinical Trial Protocol 01  all 08 December 2020 , Version 1 (electronic 1.0)  
Original Protocol  all 03 September 2020,  Version 1 (electronic 2.0)  
Amended protocol 0 3 (25 Jan 2021) 
This amended protocol 03 (Amendment 03) is not considered to be substantial  based on the 
criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the 
Council of the European Union.  
OVERALL RATIONALE FOR THE AMENDMENT   
Changes in the protocol have been implemented to address MHRA requests . 
PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Section # and Name  Description of Change  Brief Rationale  
2.3 Benefit/Risk 
Assessment  Added information on the benefits and risks of transitioning 
from sutimlimab to BIVV020  MHRA request  
4.2 Scientific rationale for 
study design  Added information on the rationale for transitioning patients 
who previously responded to sutimlimab to BIVV020  MHRA request  
5.1 Inclusion criteria I05  Restrictions on participant sperm and ova donation added  MHRA request  
5.2 Exclusion criteria E08  Participants switching from sutimlimab may be enrolled 
even with a positive SARS -CoV-2 test, based on the 
judgement of the Investigator  These participants may be at risk 
for severe thrombocytopenia if 
they are unable to receive either 
sutimlimab or BIVV020  
7.1.1 Permanent 
discontinuation  Added language stating that the replacement of a 
participant who discontinued from the study will not occur in 
the case where the participant was discontinued due to a 
BIVV020 -related adverse reaction or safety concern  MHRA request  
8.2.2 Vital signs; 
8.2.3  Electrocardiograms  Previous requirements for vital signs assessments and 
electrocardiograms to be conducted prior to clinical 
laboratory assessments have been changed to 
recommendations  This order of procedures  is no t 
feasible at some sites  
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 3 TABLE  OF CONTENTS  
AMENDED CLINICAL TRI AL PROTOCOL 03  ................................ ................................ ..............................  1 
PROTOCOL AMENDMENT S UMMARY OF CHANGES  ................................ ................................ ...............  2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................................ .. 3 
LIST OF TABLES  ................................ ................................ ................................ ................................ ...........  7 
LIST OF FIGURES  ................................ ................................ ................................ ................................ ..........  7 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ .................  8 
1.1 SYNOPSIS  ................................ ................................ ................................ ................................ ....... 8 
1.2 SCHEMA  ................................ ................................ ................................ ................................ ........  13 
1.3 SCHEDULE OF ACTIVI TIES (SOA)  ................................ ................................ ..............................  14 
2 INTRODUCTION  ................................ ................................ ................................ ............................  19 
2.1 STUDY RATIONALE ................................ ................................ ................................ ......................  19 
2.2 BACKGROUND  ................................ ................................ ................................ .............................  19 
2.3 BENEFIT/RISK ASSESSM ENT ................................ ................................ ................................ ..... 20 
2.3.1  Risk assessment  ................................ ................................ ................................ ............................  24 
2.3.2  Benefit assessment  ................................ ................................ ................................ ........................  26 
2.3.3  Overall benefit: risk conclusion  ................................ ................................ ................................ ...... 26 
3 OBJECTIVES AND  ENDPOINTS  ................................ ................................ ................................ . 27 
3.1 APPROPRIATENESS OF M EASUREMENTS  ................................ ................................ ..............  28 
4 STUDY DESIGN  ................................ ................................ ................................ ............................  29 
4.1 OVERALL DESIGN  ................................ ................................ ................................ ........................  29 
4.2 SCIENTIFIC RATIONALE  FOR STUDY DESIGN  ................................ ................................ .........  30 
4.2.1  Participant input into design  ................................ ................................ ................................ ...........  31 
4.3 JUSTIFICATION FOR DO SE ................................ ................................ ................................ ........  31 
4.4 END OF STUDY DEFINITIO N ................................ ................................ ................................ ....... 31 
5 STUDY POPULATION  ................................ ................................ ................................ ..................  32 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ ..................  32 
5.2 EXCLUS ION CRITERIA  ................................ ................................ ................................ ...............  33 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 4 5.3 LIFESTYLE CONSIDERAT IONS  ................................ ................................ ................................ ... 35 
5.4 SCREEN FAILURES ................................ ................................ ................................ ......................  35 
5.5 CRITERIA F OR TEMPORARILY DELAY ING ENROLLMENT/STUDY  INTERVENTION 
ADMINISTRATION  ................................ ................................ ................................ ........................  35 
6 STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY  ................................ ...................  36 
6.1 STUDY INTERVENTION(S ) ADMINISTERED  ................................ ................................ ..............  36 
6.1.1  Intravenous loading dose administration  ................................ ................................ .......................  36 
6.1.2  Subcutaneous dose administration  ................................ ................................ ................................  37 
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY................................ .......................  38 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  ................................ ....... 38 
6.4 STUDY INTERVENTION C OMPLIANCE  ................................ ................................ ......................  38 
6.5 DOSE MODIFICATION  ................................ ................................ ................................ ..................  39 
6.6 CONTINUED ACCESS TO INTERVENTION AFTER T HE END OF THE STUDY .......................  39 
6.7 TREATMENT OF OVERDOS E ................................ ................................ ................................ ...... 39 
6.8 CONCOMITANT THERAPY  ................................ ................................ ................................ ..........  40 
6.8.1  Rescue medicine  ................................ ................................ ................................ ............................  40 
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ...........................  41 
7.1 DISCONTINUATION OF S TUDY INTERVENTION  ................................ ................................ ..... 41 
7.1.1  Permanent discontinuation  ................................ ................................ ................................ ............  41 
7.1.2 Liver chemistry stopping criteria  ................................ ................................ ................................ .... 42 
7.1.3  QTc stopping criteria  ................................ ................................ ................................ ......................  42 
7.1.4  Lack of efficacy (relapse or sustained lack of improvement) stopping criteria  ..............................  42 
7.1.5  Thrombocytosis  ................................ ................................ ................................ ..............................  42 
7.1.6  Tempor ary discontinuation  ................................ ................................ ................................ .............  42 
7.2 PARTICIPANT DISCONTI NUATION/WITHDRAWAL F ROM THE STUDY  ................................ .. 43 
7.3 LOST TO FOLLOW UP  ................................ ................................ ................................ .................  43 
8 STUDY ASSE SSMENTS AND PROCEDUR ES ................................ ................................ ...........  45 
8.1 EFFICACY ASSESSMENTS   ................................ ................................ ................................ ........  45 
8.2 SAFETY ASSESSMENTS  ................................ ................................ ................................ ............  45 
8.2.1  Physical examinations  ................................ ................................ ................................ ...................  45 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 5 8.2.2  Vital signs  ................................ ................................ ................................ ................................ ....... 46 
8.2.3  Electrocardiograms  ................................ ................................ ................................ ........................  46 
8.2.4  Clinical safety laboratory assessments  ................................ ................................ ..........................  46 
8.2.4.1  Additional testing in case of hypersensitivity/allergic reaction  ................................ .......................  47 
8.2.4.2  Additional testing in case of suspected rhabdomyolysis ................................ ................................  47 
8.2.5  Pregnancy testing  ................................ ................................ ................................ ..........................  47 
8.2.6  Vaccinations against encapsulated bacteria  ................................ ................................ ..................  47 
8.2.7  Injection site reactions  ................................ ................................ ................................ ...................  48 
8.2.8  Phone calls  ................................ ................................ ................................ ................................ ..... 48 
8.2.9  Participant diary  ................................ ................................ ................................ .............................  48 
8.3 ADVERSE EVENTS (AES) , SERIOUS ADVERSE EV ENTS (SAES) AND OTHE R 
SAFETY REPORTING  ................................ ................................ ................................ ...................  48 
8.3.1  Time period and frequency for collecting AE and SAE information  ................................ ...............  49 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ...............................  49 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ................................ ...........  49 
8.3.4 Regulatory reporting requirements for SAEs  ................................ ................................ .................  50 
8.3.5  Pregnancy  ................................ ................................ ................................ ................................ ...... 50 
8.3.6  Adverse event of special interest  ................................ ................................ ................................ ... 51 
8.3.7  Guidelines for reporting product complaints  ................................ ................................ ..................  52 
8.4 PHARMACOKINETICS  ................................ ................................ ................................ ..................  52 
8.4.1  Sampling times  ................................ ................................ ................................ ...............................  52 
8.4.2  Sample handling procedure  ................................ ................................ ................................ ...........  52 
8.4.3 Bioanalytical methods  ................................ ................................ ................................ ....................  52 
8.4.4  Pharmacokinetic parameters  ................................ ................................ ................................ .........  52 
8.5 GENETICS AND/OR PHAR MACOGENOMICS  ................................ ................................ ............  52 
8.6 BIOMARKERS  ................................ ................................ ................................ ...............................  52 
8.7 IMMUNOGENICITY  ASSESSMENTS  ................................ ................................ ...........................  53 
8.8 HEALTH ECONOMICS OR MEDICAL RESOURCE UTI LIZATION AND HEALTH 
ECONOMICS  ................................ ................................ ................................ ................................ . 53 
8.9 USE OF BIOLOGICAL SA MPLES AND DATA FOR F UTURE RESEARCH  ................................  53 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..............................  55 
9.1 SAMPLE SIZE DETERMIN ATION  ................................ ................................ ................................ . 55 
9.2 POPULATIONS FOR ANAL YSES  ................................ ................................ ................................ . 55 
9.3 STATISTICAL ANALYSES  ................................ ................................ ................................ ............  55 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 6 9.3.1  General considerations  ................................ ................................ ................................ ..................  55 
9.3.2  Primary endpoint  ................................ ................................ ................................ ............................  56 
9.3.3  Seco ndary endpoints  ................................ ................................ ................................ .....................  56 
9.3.4  Exploratory endpoints  ................................ ................................ ................................ ....................  57 
9.3.5  Safety analysis  ................................ ................................ ................................ ...............................  57 
9.3.5.1  Adverse events  ................................ ................................ ................................ ..............................  57 
9.3.5.2  Laboratory variables and vital signs ................................ ................................ ...............................  57 
9.3.6  Other analysis  ................................ ................................ ................................ ................................  57 
9.4 INTERIM ANALYSES  ................................ ................................ ................................ ...................  58 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  ........................  59 
10.1  APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT CONSIDE RATIONS  ....... 59 
10.1.1  Regulatory and ethical considerations  ................................ ................................ ...........................  59 
10.1.2  Financial disclosure ................................ ................................ ................................ ........................  60 
10.1.3  Informed consent process  ................................ ................................ ................................ ..............  60 
10.1.4  Data protection  ................................ ................................ ................................ ...............................  61 
10.1.5  Review Committees  ................................ ................................ ................................ .......................  63 
10.1.6  Dissemination of clinical study data  ................................ ................................ ...............................  64 
10.1.7  Data quality assurance  ................................ ................................ ................................ ..................  64 
10.1.8  Source documents  ................................ ................................ ................................ .........................  65 
10.1.9  Study and site start and closure  ................................ ................................ ................................ ..... 65 
10.1.10  Publication policy  ................................ ................................ ................................ ...........................  66 
10.2  APPENDIX 2: CLINICAL  LABORATORY TESTS  ................................ ................................ .........  67 
10.3  APPENDIX 3: AES AND SAES: DEFINITIONS AN D PROCEDURES FOR REC ORDING, 
EVALUATING, FOLLOW -UP, AND REPORTING  ................................ ................................ .........  68 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............................  68 
10.3.2  Definition of SAE  ................................ ................................ ................................ ............................  70 
10.3.3  Recording and follow -up of AE and/or SAE  ................................ ................................ ...................  71 
10.3.4  Reporting of SAEs ................................ ................................ ................................ ..........................  73 
10.4  APPENDIX 4: CONTRACE PTIVE AND BARRIER GU IDANCE  ................................ ...................  74 
10.4.1  Definitions  ................................ ................................ ................................ ................................ ...... 74 
10.4.2  Contrac eption guidance  ................................ ................................ ................................ .................  75 
10.5  APPENDIX 5: GENETICS  ................................ ................................ ................................ .............  76 
10.6  APPENDIX 6: SAFETY: SUGGESTED ACTIONS AN D FOLLOW -UP ASSESSME NTS .............  77 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 7 10.7  APPENDIX 7: AES, ADE S, SAES, SADES, USAD ES AND DEVICE DEFICI ENCIES: 
DEFINITIONS AND PROC EDURES FOR RECORDING , EVALUATING, FOLLOW -UP, 
AND REPORTING IN MED ICAL DEVICE STUDIES  ................................ ................................ .... 80 
10.8  APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENT S ................................ ..............................  80 
10.9  APPENDIX 9: CONTINGE NCY MEASURES FOR A R EGIONAL OR NATIONAL 
EMERGENCY THAT IS DE CLARED BY A GOVERNME NTAL AGENCY  ................................ ... 80 
10.10  APPENDIX 10: ABBREVI ATIONS  ................................ ................................ ................................ . 81 
10.11  APPENDIX 11: PROTOCO L AMENDMENT HISTORY  ................................ ................................  83 
11 REFERENCES  ................................ ................................ ................................ ...............................  86 
 
LIST OF TABLES   
Table  1 - Risk assessment  ................................ ................................ ................................ ............................  24 
Table  2 - Objectives and endpoints  ................................ ................................ ................................ ...............  27 
Table  3 - Overview of study interventions administered  ................................ ................................ ...............  36 
Table  4 - Arms and associated interventions  ................................ ................................ ................................  36 
Table  5 - Populations for analyses  ................................ ................................ ................................ ................  55 
Table  6 - Protocol -required laboratory tests  ................................ ................................ ................................ .. 67 
Table  7 - Highly effective contraceptive methods  ................................ ................................ .........................  75 
 
LIST OF FIGU RES  
Figure  1 - Graphical study design  ................................ ................................ ................................ .................  13 
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 8 1 PROTOCOL SUMMARY   
1.1 SYNOPSIS   
Protocol title:   
A multicenter, Phase 2a, open -label, non -randomized study evaluating the efficacy, 
safety, and tolerability of BIVV020 in adults with persistent/ chronic immune 
thrombocytopenia (ITP)  
Brief  title:  A Phase 2a study evaluating BIVV020 i n adults with persistent/chronic immune 
thrombocytopenia (ITP)  
Rationale:  
Individuals  with i mmune thrombocytopenia (ITP)  who are refractory to current therapies may 
respond to inhibition of the proximal portion of the classical complement pathway  (CP). This 
hypothesis is supported by data obtained using  a first -generation CP inhibitor, sutimlimab  
(BIVV009) , which targets the active and inactive conformations of human serine protease 
complement component 1, s subcomponent (C1s) . The current study will assess the efficacy, 
safety, and tolerability of a second -generation CP inhibitor, BIVV020. BIVV020 selectively 
targets the activate conformation  of C1s and has a prolonged half -life comp ared to sutimlimab , 
allowing for subcutaneous (SC) maintenance administration.  This study will enroll participants 
who have received  sutimlimab in study TDR16218 as well as participants who have not 
previously received sutimlimab (naïve participants).  
Objectives and endpoints   
 
 
Objectives  Endpoints  
Primary  
• To evaluate the effect of BIVV020 on the 
durability of platelet response  in participants 
with persistent/chronic i mmune 
thrombocytopenia  (ITP)  • Naïve participants: Proportion of participants with a 
platelet count ≥50 × 109/L at ≥50% of scheduled visits , 
or for participants with baseline platelet count 
<15 × 109/L, a ≥20 × 109/L increase in platelet count 
from baseline at ≥50% of scheduled visits , without 
receiving rescue ITP therapy, as assessed  from Week  3 
to Week 24.  
• Participants who previously received sutimlimab: 
Proportion of participants with maintenance of platelet 
coun t ≥30 × 109/L at ≥50% of scheduled visits , without 
receiving rescue ITP therapy, as assessed from Week 3 
to Week 24.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 9 Objectives  Endpoints  
Secondary  
• To assess the safety and tolerability of 
BIVV020  • Standard clinical and laboratory parameters and 
adverse events  
• To assess the pharmacokinetic s (PK)  of 
BIVV020  • Plasma concentrations of BIVV020  
• To assess the response rate of treatment with 
BIVV020  • Response rate at Weeks 24 and 52, defined as a 
platelet count ≥50 × 109/L and a greater than 2 -fold 
increase from  baseline, measured on 2 occasions at 
least 7 days apart, with the absence of bleeding 
(bleeding is defined as bleeding with a score ≥2 on the 
WHO bleeding scale) , and the lack of combination ITP 
therapy during this period.  
• To assess the time to response  • Time  from baseline  to first platelet response , defined as 
greater than or equal to  each of the following values:  
50 × 109/L and 100 × 109/L (confirmed by 
2 measurements  at least 7  days apart ) 
• To assess the effect of treatment with BIVV020 
on the requirement for rescue ITP therapy  • Proportion of participants who did not require rescue 
therapy for an acute episode of thrombocytopenia after 
Week 3  
• To assess the immunogenicity of BIVV020  • Incidence and titer (if relevant) of anti -BIVV020 
antibodies  
 
 
Exploratory  
 
 
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 10 Overall design:  
This is a Phase 2a , open -label, non -randomized, international, multicenter study to evaluate the  
efficacy,  safety, and tolerability of BIVV020 in adults with persistent/ chronic primary ITP. The 
study will enroll approximately 12 participants: up to  6 participants  who have received  and 
responded to  sutimlimab  (BIVV009)  in study TDR16218, as well as  participants who have not  
previously received sutimlimab.  
The Screening Period will be up to 56 days. Screening begins from the time of the signing of the 
informed consent form  (ICF) . For participants receiving sutimlimab in study TDR16218, they 
may continue to receive sutimlimab during screening, until at least  14 days prior to the first dose 
of BIVV020 , as duration of the PD effect of sutimlimab is approximately 14 days. This period  
between the final dose of sutimlimab  and the first dose of BIVV020 is known as the Transition 
Period. Enrollment in the study occurs when a participant receives the first dose of BIVV020 . 
A loading dose of BIVV020 at 50 mg/kg intravenous ( IV) will be administered on Day 1, 
followed by maintenance dose s of 600 mg SC weekly  starting on Day  8. On Day 1, participants 
will remain in the clinic for at least 4 hours after  the start of  investigational medicinal product 
(IMP) administration. The 600 mg SC dose will be administered as two 2  mL injections. For the 
first 5 weeks of maintenance therapy, the injections will be performed  by the site sta ff, and  
participants will receive education on self -administration. At W eek 6, the participant (or their 
caregiver) will perform the injection under the supervision of the site staff. Participants should be 
observed for 30 minutes after the first 6 SC admi nistrations of IMP.  
From Weeks 7 to 12, participant s will return to the clinic every other week. During the weeks they 
are not seen in the clinic, they will administer BIVV020 at home. At clinic visits, participants 
(or their caregiver) will administer BIVV020 under the supervision of the study staff. Participants 
may request assistance with the injections from the study staff during these visits. From Weeks 13  
to 24, participants  will return  every 4  weeks  and will self -administer BIVV020  under the 
supervision of study staf f at those visits . From Week 25 onward, visits will occur at a minimum of 
every 8 weeks , and participants will continue to self -administer BIVV020 under the supervision 
of the study staff during those visits . Clinic visi ts should  be scheduled so that they align as closely 
as possible with the day the participant typically takes BIVV020 . If a participant prefers for drug 
administration to occur at the site instead of his/her home at any time during the study, this is 
accep table.  
Phone calls will be performed  during the study for site staff to remind  participants to take their 
injections , answer any questions they may have  regarding the injections , and to assess adverse 
events ( AEs). From Weeks 7  to 24, phone calls will be performed on weeks that the participant s 
are not seen in the clinic (Weeks 7, 9, 11, 13  to 15, 17  to 19, and 21  to 23). After Week 25, phone 
calls will be performed approximately 4 weeks after each previous visi t. (If a visit  during this 
period  occurs within approximately 4 weeks of the prior visit, a phone call is not necessary ) 
Phone calls should continue to occur approximately every 8 weeks after the cessation of 
treatment, until the End of Study (EOS) visit.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 11 Maintenance injections will continue until the last participant enrolled has completed 52 weeks of 
treatment . Therefore, the length of maintenance therapy may vary for each participant . The 
maximum duration of treatment for an individual participant is 104  weeks.  
Brief summary : Phase 2  
This is a single group  treatment , Phase 2 a, open -label , single  arm study of BIVV020 in male and 
female  participants with persistent/ chronic ITP . 
Study duration:  
• Screening Period: up to 56 days  
• Transition Period between last sutimlimab dose and first dose of BIVV020 (for 
participants who were previously receiving sutimlimab): at least 14 days, included as part 
of the 56 -day Screening Period  
Treatment duration : 52 weeks  (minimum)  
Visit frequency:  
• Day 1  
• Day 4  
• Weeks 1  to 6: Weekly  
• Weeks 7 to 12: Every other week  
• Weeks 13  to 24: Every 4 weeks  
• Weeks 2 5+: At least every 8 weeks  
• End of Study visit: 22 weeks after the last dose of BIVV020  
Number of participants:  
Approximately 12 participants will be enrolled . Since there is no statistical hypothesis to be tested 
in this study, the sample size is not determined statistically.   
Intervention  groups and duration : 
All participants will receive the study intervention.  
Study intervention : BIVV020  
Investigational  medicinal product : 
• Formulation:  BIVV020 supplied in single use vials containing 750 mg (150 mg/mL; 
extractable volume of 5 mL)  
• Routes of administration:  IV loading dose; SC maintenance administration  
• Dose regimen : 50 mg/kg IV loading dose, followed by 600 mg SC weekly  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 12 Noni nvestigational medicinal product : Not applicable  
Devices:  Not applicable  
Posttrial access to study medication :  
Participants will continue to receive BIVV020 until the last participant enrolled has completed 
52 weeks of treatment . After that time, a long -term extension study may be available for 
participants to continue to receive BIVV020.  
• Interim analysis  
An interim analysis will be conducted when approximately  12 participants have each been 
treated for 15 weeks.   
• Primary endpoint  
The proportion  (and number)  of responders fulfilling the criteria in the primary endpoint 
will be presented; the 95% confidence interval for the proportion of responders will be 
estimated with Clopper -Pearson  method.  
• Secondary endpoints  
All secondary endpoints will be summarized using descriptive statistics. For categorical 
endpoints, number  and proportion of participants will be presented; for continuous 
endpoints, mean, standard deviation, median, and other  appropriate statistics will be 
presented; for time -to-event endpoints, Kaplan -Meier methods will be used to estimate 
median time -to-event.   
Data Monitoring /Other  committee: Yes 
This study will have a Study Monitoring Committee, compris ing at least 2 investigators 
participating in the study and Sponsor representatives.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 13 1.2 SCHEMA   
 
Figure  1 - Graphical study design   
 
D = Day; EOS  = end of study; IV  = intravenous ; SC = subcutaneous  
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 18 j Height at screening only . 
k To be performed at Weeks 8 and 12 only.  
l In addition to the IMP being dispensed in the clinic, the IMP may be dispensed for home administration via DTP services , except if prohibited by local regulatory authorit ies.  
m Injecti ons will be administered by site staff at visits that occur during Weeks 1  to 5. Participants will perform the injection in the clinic on Week 6 under the supervision of study staff.   
n At visits th at occur s from Week 7 onward,  injections will be performed in the clinic by the participants, under the supervision of study staff.   
o See Section  8.2.2 . 
p See Section  8.2.1 . Ad-hoc physical exam s may be performed at the discretion of the I nvestigator based on any AEs reported by the participant . 
q See Section  10.2 for a list of tests to be performed. Labs should be performed prior to drug administration.   
r To be performed at Week  24 only . 
s See Section  8.2.7 . 
t Participants will record IMP administrations in a paper or e -diary when performing administrations at hom e. 
u Phone calls will be performed  to remind participants to take their injections , answer any questions they may have  regarding the injections, and to assess AEs. From Weeks 7  to 24, phone calls will be performed on 
weeks that the participant s are not seen in the clinic (Weeks 7, 9, 11, 13  to 15, 17  to 19, and 21  to 23). A fter Week 25 , phone calls will be performed approximately 4 weeks after each previous visit . (If a visit during 
this period occurs within approximately 4 weeks of the prior visit,  a phone call is not necessary. ) Phone calls should continue to occur approximately every 8 weeks after the cessation of treatment , until the EOS 
visit. 
v To be performed prior to drug administration unless otherwise noted.  
w Platelet count should not be perfo rmed as a separate test at visits when a complete blood count is performed.  
x If participant provided consent  for future research . 
y To be performed at Week 12 only.  
z Participants with positive ADA titers at the last visit of the treatment period will continue to have ADA titers  drawn every 8 weeks until titers  are decreasing , or until the EOS visit . 
Abbreviations: Ab : antibody; ADA: antidrug  antibodies ; AE: adverse event; D: day; DTP: Direct -to-Patient ; ECG : electrocardiogram; ECOG: Eastern Cooperative Oncology Grou p; EOS: End of Study; FSH: follicle 
stimulating hormone, HIV: human immunodeficiency virus; HB : hepatitis B; HC V: hepatitis C virus; Ig: immunoglobulin; IMP: investigational medicinal product; IV: intravenous; PD: pharmacodynamics; 
SARS  CoV-2: severe acute respiratory syndrome coronavirus 2; SC: subcutaneous; SLE: systemic lupus erythematosus;  WOCBP: Women of childbearing potential . 
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 19 2 INTRODUCTION   
BIVV020 is a humanized monoclonal antibody that binds to and selectively inhibits the activated 
form of human serine protease C1s . BIVV020 is a second generation classical complement 
inhibitor with a modified mechani sm of action compared to its predecessor, sutimlimab  in ITP , 
which binds to the non -activated and activated conformations of C1s. Due to t he lower 
concentration of activated C1s compared to total C1s, BIVV020 is not expected to be cleared 
rapidly by target -mediated drug disposition , as is the case for sutimlimab . By selectively targeting 
only the activated conformation of C1s, the clearance of BIVV020 is reduced and its half-life 
prolonged compared to its predecessor.  
The complement system consists of a network of over 30 soluble and membrane -bound plasma 
proteins that upon activation result in an enzymatic cascade responsible for the clearance of 
pathogens and immune complexes  (1). Along with subcomponents C1r and C1q, C1s sits at the 
apex of the classical pathway of the complement system . By binding to activated C1s, BIVV020 
prevents enzymatic action of the C1 complex on its substrates, complement factors C4 and C2, 
and thereby blocks formation of the C3 co nvertase. The result is  the inhibition of CP activity 
proximal to C3 , which allows the alternative and lectin pathways to remain functionally intact for 
the purpose of host defense. The CP has been implicated in many diseases that are driven by the 
presenc e of a pathogenic antibody . Immune thrombocytopenia , and particularly ITP that is 
refractory to other treatments,  is one such example.  
2.1 STUDY RATIONALE   
Individuals  with ITP who are refractory to current therapies may respond to inhibition of the 
proximal portion of the CP. This hypothesis is supported by data obtained using a first -generation 
CP inhibitor , sutimlimab, which  targets the activ e and inactive  conformation s of human serine 
protease  C1s. The current study will assess the efficacy, safety, and tolerability of a 
second -generation CP inhibitor , BIVV020. BIVV020 selectively targets the activated 
conformation C1s and has a prolonged  half-life compared with sutimli mab, allowing for SC 
maintenance administration . 
2.2 BACKGROUND   
Immune thrombocytopenia is an autoimmune disorder characterized by immunologic destruction 
of platelets in respons e to an unknown stimulus. Immune thrombocytopenia  may be either a 
primary or secondary disorder. Secondary causes of ITP include autoimmune disorders 
(eg, antiphospholipid antibody syndrome), viral infections (eg,  human immunodeficiency virus 
[HIV], hepatitis C virus [HCV ]), and certain drugs. Decreased platelet levels are caused by 
increased platelet destruction as well as decreased platel et production .  
Patients  with ITP are typically first treated with oral corticosteroids and intravenous 
immunoglobulin  (IVIg ). The goal of treatment is to prevent major bleeding rather than to 
normalize  the platelet count. Splenectomy had been recommended for patients who failed initial 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 20 therapy, although given the long -term risks for infection, this recommendation has recently been 
revisited. Second -line treatment includes azathioprine, cyclospo rine A, cyclophosphamide, 
danazol, dapsone, mycophenolate mofetil, rituximab, and thrombopoietin receptor agonists 
(such as eltrombopag and romiplostim). Each agent has potential toxicities including immune 
suppression, secondary malignancies, hypertension , and liver dysfunction.  
Some ITP patients will be refractory or unresponsive to existing therapy, and it has been 
postulated that complement -mediated platelet destruction may play a prominent role in these 
patients. It has been demonstrated that plasma au toantibodies from ITP patients can activate 
complement on the surface of normal human platelets  (2, 3). The proportion of ITP patients 
whose samples were capable of activating complement consistently  was approximately 50% in 
these studies. T he ability of ITP patient autoantibodies to activate complement on the platelet 
surface was significantly inhibited by the specific CP inhibitor TNT003 (a precursor to 
sutimlimab ), including inhibition of downstream split products of the classical pathway cascade 
such as C4d and the membrane attack complex C5b -9 (4). Of note, ITP patients with 
autoantibodies capable of activating complement also  have reduced platelet production ( 2, 4). Due 
to the characteristics of complement -mediated activation, currently available therapies for ITP 
would not be expected to be effective in the subset of patients with significant complement -
mediated platelet destruction. For example, complement -opsonized particles and blood cells are 
removed from circulation by the liver, and thus, it would not be expected that splenectomy would 
be effective in this population , similar to observations in other classical complement -mediated 
diseases lik e cold agglutinin disease  (CAD) (5). Therefore , it is likely that a proportion of ITP 
patients, and a substantial proportion of patients with refractory or unresponsive disease , may be 
amenable to therapy with a CP inhibitor such as BIVV0 20.  
2.3 BENEFIT/RISK ASSESSM ENT  
The human safety risk from short -term inhibition of the complement system  in general  appears to 
be low, based on the experience with 5 approved products in this therapeutic class. Long -term, 
complement inhibition may increase the risk of infection with encapsulated bacteria, as reflected 
in the product l abel for eculizumab (Soliris®), an inhibitor of the terminal portion of the 
complement system. To mitigate this risk,  this study includes an appropriate program of 
prophylactic vaccinations.  
The risks  associated with long -term inhibition of the proximal po rtion of the  classical pathway  in 
particular  are unknown. Theoretically, such inhibition could increase the risk of systemic lupus 
erythematosus ( SLE) or circulating immune complexes  (CIC)  disease due to the role of the C1 
complex in immune complex clearance, as observed in patients with congenital deficiencies of C1 
complex components (C1q,  C1s, and C1r). However, pharmacologic inhibition of C1s differs 
from congenital deficiency of the C1  complex because: 1)  congenital C1 complex component 
deficiency is commonly associated with second mutations in other immune system genes; 
2) pharmacologic inhibition of C1s enzymatic function in the C1 complex leaves intact the 
non-enzymatic function of C 1q, which is important for the opsonization and phagocytic removal 
of apoptotic cells , which protects against autoimmunity; and 3) the phenotype associated with 
life-long, often total absence of C1 complex structure and function is unlikely to be reproduce d by 
pharmacologic antagonism of C1 enzymatic function in fully developed adults. Nevertheless, 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 21 standard clinical biomarkers related to SLE (eg, antibodies to double -stranded DNA [dsDNA ]) 
have been incorporated into the study as safety surveillance measure s. 
The risk -benefit profile of BIVV020 is supported by nonclinical toxicology studies, data from 
first-in-human  (FIH ) studies in healthy adult participants, and the BIVV009 clinical development 
experience, including preliminary data from an ongoing Phase 1b study of BIVV009 in chronic 
ITP patients (TDR16218 ). 
Nonclinical toxicology studies  did not reveal any target organs for BIVV020. There were no 
autoimmune findings in a 5 -week  toxicity study. No binding o r cross -reactivity with off -target 
tissues ha s been observed. No reproductive or developmental toxicology study has been 
performed to date. Listed below are the  preclinical studies that support the current BIVV020 
safety profile:  
• Good Laboratory Practice ( GLP ) 5-week repeat -dose toxicity study (IV and SC) in 
cynomolgus monkeys with a 4 -week recovery period  
• GLP 26 -week repeat  dose toxicity study (IV and SC) in cynomolgus monkeys with an 
8-week recovery period  
• GLP tissue cross -reactivity study in normal human tissues  
• GLP in vitro hemolysis and plasma flocculation study  
Results of the recently completed FIH, randomized, double -blind, placebo -controlled study of the 
safety, tolerability, pharmacoki netics  (PK), and pharmacodynamics  (PD) of ascending single and 
repeated doses of BIVV020 in healthy adult participants (TDU16308 -TDR16309) demonstrated 
that BIVV020 has an acceptable safety and tolerability profile while providing dose -dependent 
inhibition of CP activity in healthy adult participants.  
• No deaths, treatment -emergent serious adverse events ( TESAEs) or treatment -emergent 
severe AEs were reporte d. Stopping criteria were not met by any participant or cohort. 
There were no events of serious hypersensitivity and/or anaphylaxis, meningococcal 
infection, SLE. Preliminary review noted no trend or dose relationship in laboratory data, 
vital signs, or el ectrocardiogram  (ECG ) parameters.  
• Two AEs of special interest (AESIs), meeting AESI criteria of alanine aminotransferase 
(ALT ) ≥2 x upper limi t of normal (ULN ) were reported:  
- An AESI of rhabdomyolysis was reported in 1 subject 7 days after BIVV020 600 mg 
SC dose (peak creatine phosphokinase =  215 × ULN) and assessed as related to study 
drug (TDU16308). The subject performed hot yoga and consumed alcohol 2 days prior 
to the event. The event resolved 15 days later without any corrective intervention. 
Of note, one non -serious AE of rhabdomyolysis in upp er arms due to  heavy exertion 
was also reported in another subject from  the placebo cohort (peak creatine 
kinase  = 78.5 × ULN, peak aspartate aminotransferase ( AST ) = 6.1 × ULN, 
peak  ALT  = 1.7  × ULN).  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 22 - An AESI of hepatic steatosis (peak ALT value 218 U/l, ULN: 52) was reported in 
1 subject after receiving 4 weekly doses of 300 mg SC BIVV020 on Day 55. The event 
was assessed as related to study drug and resolved 92 days later without any corrective 
interv ention (TDR16309).  
Another Sanofi C1s inhibitor, BIVV009, is currently in Phase 3 development for complement 
mediated diseases, including CAD. BIVV009 is being studied in patients with ITP.  As of 11 July 
2019, an estimated 162 participants (96 healthy volu nteers and 34 patients with CAD as well as 
32 patients with other complement -mediated disorders, including ITP as of 11 April 2019) have 
been exposed to BIVV009 in the clinical development program. BIVV009 appeared to be 
generally well -tolerated based on t he safety data.  
As of 11 July 2019, there were no reports of meningococcal infection, SLE, or newly developed 
autoimmune conditions, serious hypersensitivity and/or anaphylaxis in BIVV009 clinical trials.  
Serious infections have been reported in BIVV009 c linical trials in patients with CAD, including  
streptococcal sepsis ( Streptococcus pyogenes ), Escherichia coli sepsis, wound infection 
staphylococcal ( Staphylococcus aureus  and Staphylococcus epidermidis ) and pneumonia 
(organism unknown).  Overall, the pattern of infections in patients with CAD was consistent with 
an older, often medically complex patient population, including some patients who received 
chronic immunomodulatory therapies.  
As of 21 June 2020, t welve chronic ITP patients were enrolled in the ongoing BIVV009 study 
TDR16218. Clinical response, defined by a platelet count greater than 50 × 109/L measured on 
2 separate occasions more than 7 days apart, was achieved by 50% of participants, and 
thrombocytopenia reoccurred during  the washout perio d at the end of Part A.  Platelet levels 
improved again in all patients who qualified for retreatment in Part B  to date . 
As of 09 April 2020, 12 ITP patients had received at least 1 dose of sutimlimab in the TDR16218 
study part A, with 6 patients having rec eived at least 20 weeks of sutimlimab treatment in Part A 
and 6 patients continuing into the long -term safety extension study Part B. As of 09 April 2020, 
4 of these patients had completed an additional 65 -85 weeks of sutimlimab treatment in 
TDR16218 Part B, with an acceptable safety profile and evidence of a sustained therapeutic 
effect. No new safety concerns were identified with long -term sutimlimab treatment. Four patients 
continue d to receive sutimlimab in study  TDR16218 as of 29 September 2020.  
Whethe r inhibition of the proximal portion of the  CP may increase the risk of severe acute 
respiratory syndrome coronavirus 2 (SARS -CoV -2) infection is unknown. Complement -mediated 
neutralization has been described for many vir al infections , with all pathways (classical, 
alternative, and lectin) shown to be involved, depending on the particular virus  (6). Thus, the 
effect of CP inhibition on the risk of SARS -CoV -2 infection is unclear. Of note, there is also 
evidence to suggest that complement activation may play a role in the pa thogenesis of the disease 
(7). If this is indeed the case, complement pathway inhibition may in fact limit the severe 
manifestations of the di sease.  
For participants who transition from sutimlimab to BIVV020, the efficacy of BIVV020 is  
expected to be similar to that of sutimlimab, as both target the same protein, C1s, and inhibit CP.  
While it is expected that patients who responded to sutimlima b will have a similar response to  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 23 BIVV020, there remains the possibility that the response to BIVV020 may differ from that to  
sutimlimab in some patients. The target -specific and mechanism -related risks are expected to be  
the same for both sutimlimab and B IVV020. Patients who transition from sutimlimab to BIVV020  
will benefit from a decreased burden of drug administration and clinic visits over the course of the  
study, as sutimlimab is administered intravenously every other week.   
More detailed information about the known and expected benefits and risks and reasonably 
expected adve rse events of BIVV020  may be found in the Investigator’s Brochure  (IB). 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 24 2.3.1  Risk assessment   
Table  1 - Risk assessment   
Potentia l risk of clinical 
significance  Sum mary of data/rationale for 
risk Mitigation strategy  
Study intervention  
Meningococcal infection  Based on the functions of the classical 
complement pathway and evidence from 
patients with congenital classical 
complement deficiencies, or treated with 
complement inhibitors, BIVV020 may 
potentially increase risk of meningococcal 
infection as a result of long-term 
complement inhibition.  
BIVV020 FIH healthy participant 
experience:  No events of meningococcal 
infection have been reported.  
BIVV009 experience:  No reports of 
meningococcal infections in BIVV009 
clinical trials as of 21 Jun 2020. As of 
21 Jun 2020, an estimated 187 participants 
received BIVV009 in the clinical 
development program.  Participants will be monitored for 
meningococcal infection. The risk of 
meningococcal infection will be 
described in the ICFs. Participants will 
be advised to seek me dical attention if 
they develop symptoms concerning for 
meningococcal infection.  
To reduce the risk of infection, 
participants will be required to  either 
demonstrate a proof of documented 
vaccination against Neisseria 
meningitidis  within 5 years of enrollment  
or comply with the vaccination 
requirement of the protocol 
(see Section  8.2.6  for more details).  
Serio us infections  with other 
encapsulated  bacteria  Long -term complement inhibition may 
potentially increase  the risk of serious 
infections with encapsulated bacteria 
(eg: Streptococcus pneumoniae ).  
BIVV020 FIH healthy participant 
experience:  No reports of serious infections 
with encapsulated bacteria.  
BIVV009 experience:  Serious infections 
have been reported in BIVV009 clinical trials 
in patients with CAD,  although not 
necessarily with encapsulated organisms.  
These include streptococcal sepsi s 
(Streptococcus pyogenes ), Escherichia coli 
sepsis, wound infection staphylococcal 
(Staphylococcus aureus  and 
Staphylococcus epidermidis ) and 
pneumonia (organism unknown).  Overall, 
the pattern of infections in patients with 
CAD was consistent with an olde r, often 
medically complex patient population, 
including some patients who received 
chronic immunomodulatory therapies.  Participants will be monitored for 
serious infections with encapsulated 
bacteria. The risk will be described in 
the ICFs. Participants w ill be advised to 
seek medical attention if they develop 
symptoms concerning for serious 
infections with encapsulated bacteria.  
To reduce the risk of infection, 
participants will be required to  either 
demonstrate a proof of documented 
vaccination against encapsulated 
bacteria  within 5 years of enrollment  or 
comply with the vaccination requirement 
of the protocol (see  Section  8.2.6  for 
more details).  
Systemic lupus erythematosus  Long -term CP inhibition could theoretically 
increase the risk of SLE or CIC disease due 
to the role of the C1 complex in immune 
complex clearance, as seen in patients with 
congenital deficiencies of C1 comp lex 
components (C1q, C1s, and C1r). BIVV020 Participants will be monitored for the 
development of SLE, lupus like 
syndrome,  or other autoimmune 
diseases. A clinical diagnosis of SLE is 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 25 Potentia l risk of clinical 
significance  Sum mary of data/rationale for 
risk Mitigation strategy  
inhibits the C1s enzymatic function in the 
C1 complex. However, pharmacologic 
inhibition of C1s does not necessarily 
equate to congenital deficiency of the C1 
complex.  
 Preclinical data:  No autoimmune 
response (C ICC1q; ANAs) was observed in 
a 5-week repeat -dose toxicity study in 
cynomolgus monkeys.  
BIVV020 FIH healthy participant 
experience : No reports of SLE or newly 
developed autoimmune conditions.  
BIVV009 experience : There were no 
reports of SLE or newly develo ped 
autoimmune conditions in BIVV009 clinical 
trials as of 21  June 2020. As of 21 June 
2020, an estimated 187 participants 
received BIVV009 in the clinical 
development program.  an exclusion criterion for all BIVV020 
clinical studies.  
During screening an ANA as well as 
other autoimmune antibodies will be 
checked . The Investigator may decide 
to exclude participants from the study 
who appear to be at increased risk for 
autoimmune diseases (aside from ITP).  
The risk of development of SLE will be 
described in the ICFs. A panel of 
standard clinical biomarkers related to 
SLE (eg, antibodies to double -stranded 
DNA [dsDNA]) and to CIC disease 
(eg, measurement of CICs) will be 
performed at a regular interval during 
the study . Participants who develop 
clinical manifestations of SLE or a 
confirmed SLE diagnosis will be 
terminated  early . 
Serious hypersensitivity reactions 
and/or anaphylaxis  Serious hypersensitivity reactions and 
anaphylaxis are potential risks with any 
monoclonal antibody.  
BIVV020 FIH healthy participant  
experience:  No reports of serious 
hypersensitivity reactions and/or 
anaphylaxis.  Participants will be monitore d during the 
loading dose infusion  of BIVV020  and 
immediately following infusion for any 
evidence of a hypersensitivity reaction 
or anaphylaxis.  Additionally, the first 
6 maintenance injections of BIVV020  
will occur in the clinic. If any signs or 
symptoms of an allergic reaction are 
observed during BIVV020 infusion , the 
infusion must be immediately 
discontinued, and the participant treated 
as appropriate . 
Coronavirus disease 2019 
(COVID -19) The classical pathway is involved in the 
neutralization of various viruses. Data is 
limited regarding SARS -CoV-2 in particular .  The need for SARS -CoV-2 testing 
during screening will be determined by 
the Sponsor and the Investigator at 
each site. Participants  will be counseled 
to avoid situations that may place them 
at increased risk for COVID -19. If a 
participant  is diagnosed with 
SARS -CoV-2 during the study, 
discontinu ation of  BIVV020 will be 
determined by the Investigator and 
Spons or. 
Study intervention: Risks associate d with IV infusions and SC injections (including self -administered SC injections)  
Abbreviations: ANA = antinuclear antibody; C1s = complement component 1, s subcomponent ; CAD = cold agglutinin disease ; 
CIC = circulating immune complexes; COVID -19 = coronavirus disease 2019; CP = classical complement pathway; FIH = first -in-human; 
ICF = informed consent form; ITP = immune thrombocytopenia; IV = intravenous; SARS -CoV-2 = Severe acute respiratory syndrome 
coronav irus 2 ; SC = subcutaneous; SLE = systemic lupus erythematosus  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 26 2.3.2  Benefit assessment   
Immune thrombocytopenia patients who are refractory to current therapies have substantial 
morbid ity associated with their disease, including life -threatening bleeding. Treatment with 
BIVV020 has the potential to improve platelet levels and decrease the risk of bleeding in these 
patients.  
2.3.3  Overall benefit: risk conclusion   
Considering the measures taken to minimize risk to participants  in this study, the potential risks 
identified in association with BIVV020 are justified by the anticipated benefits that may be 
afforded to part icipants with persistent/ chronic ITP. 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 27 3 OBJECTIVES AND ENDPO INTS   
Table  2 - Objectives and endpoints   
Objectives  Endpoints  
Primary  
• To evaluate the effect of BIVV020 on the 
durability of platelet response in participants 
with persistent/chronic i mmune 
thrombocytopenia  (ITP)  • Naïve participants: Proportion of participants with a 
platelet count ≥50 × 109/L at ≥50% of scheduled visits , 
or for participants with baseline platelet count 
<15 × 109/L, a ≥20 × 109/L increase in platelet count 
from baseline at ≥50% of scheduled visits , without 
receiving rescue ITP therapy, as assessed  from Week  3 
to Week 24.  
• Participants who previously received sutimlimab: 
Proportion of participants with maintenance of platelet 
count ≥30 × 109/L at ≥50% of scheduled visits , without 
receiving rescue ITP t herapy, as assessed from Week 3 
to Week 24.  
Secondary  
• To assess the safety and tolerability of 
BIVV020  • Standard clinical and laboratory parameters and adverse 
events  
• To assess the pharmacokinetic s (PK)  of 
BIVV020  • Plasma concentrations of BIVV020  
• To assess the response rate of treatment with 
BIVV020  • Response rate at Weeks 24 and 52, defined as a platelet 
count ≥50 × 109/L and a greater than 2 -fold increase 
from baseline, measured on 2 occasions at least 7 days 
apart, with the absence of bleeding (bleeding is defined 
as bleeding with a score ≥2 on the WHO bleeding 
scale) , and the lack of combination ITP therapy during 
this period.  
• To assess the time to response  • Time  from baseline  to first platelet response , defined as 
greater than or equal to  each of the following values:  
50 × 109/L and 100 × 109/L (confirmed by 
2 measurements  at least 7  days apart ) 
• To assess the effect of treatment with BIVV020 
on the requirement for rescue ITP therapy  • Proportion of participants who did not require rescue 
therapy for an acute episode of thrombocytopenia after 
Week 3  
• To assess the immunogenicity of BIVV020  • Incidence and titer (if relevant) of anti -BIVV020 
antibodies  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 28 Objectives  Endpoints  
Exploratory  
 
3.1 APPROPRIATENESS OF M EASUREMENTS   
The efficacy endpoints for this study are measures of platelet response and ITP disease severity.  
Regarding the primary endpoint, a chieving a platelet count ≥ 50 × 109/L is known to reduce  the 
risk of bleeding; for patients with a baseline platelet count <15 × 109/L, an increase of 
≥20 × 109/L would be considered clinically significant.  For patients who previously received 
sutimlimab, the endpoint seeks to demonstrate that a response due to sutimlimab is maintained 
with BIVV020.  
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 29 4 STUDY DESIGN   
4.1 OVERALL DESIGN   
• This is a Phase 2a open -label, non -randomized, international, multicenter study to evaluate 
the efficacy, safety, and tolerability of BIVV020 in adults with persistent/ chronic primary 
ITP. 
• The study will enroll approximately  12 participants: up to 6 participants  who have 
previously received and responded to sutimlimab  (BIVV009)  in study TDR16218, as well 
as participants who have not previously received sutimlimab.  
• The Screening Period will be up to 56 days. Screening begins from the time of the signing 
of the ICF. For participants receiving sutimlimab in study TDR16218, they may continue 
to receive sutimlimab during screen ing, until at least  14 days prior to the first dose of 
BIVV020 , as duration of the PD effect of sutimlimab is approximately 14  days. This 
period between the final dose of sutimlimab and the first dose of BIVV020 is known as the 
Transition Period.  
• Enrollment in the study occurs when a participant receives the first dose of BIVV020 . 
• A loading dose of BIVV020 at 50 mg/kg IV will be administered on Day 1, followed by 
maintenance dose s of 600 mg SC weekly  starting on Day 8 . On Day 1, participants will 
remain in the clinic for at least 4 hours after  that start of  IMP administration.  
• The 600 mg SC dose will be administered as two 2  mL injections. For the first 5 weeks of 
maintenance therapy, the injections will be performed by the site staff, and particip ants 
will receive education on self -administration. At W eek 6, the participant (or their 
caregiver) will perform the injection under the supervision of the site staff. Participants 
should be observed for 30 minutes after IMP administration for the first 6 SC 
administrations.  
• Starting at Week 7, the injections will be performed by the participant or caregiver at 
home. From Weeks 7  to 12, participant will return to the clinic every other week. At clinic 
visits, participants (or their caregiver) will administe r BIVV020 under the supervision of 
the study staff. Participants may request assistance with the injections from the study staff 
during these visits.  
• From Weeks 13 to 24, participants will return every 4  weeks and will self -administer 
BIVV020 under the su pervision of study staff at those visits. From Week 25 onward, visits 
will occur at a minimum of every 8 weeks, and participants will continue to 
self-administer BIVV020 under the supervision of the study staff during those visits. 
Clinic visits should be scheduled so that they align as closely as possible with the day the 
participant typically takes BIVV020.  
• If a participant prefers for drug administration to occur at the site instead of his/her home 
at any time during the study, this is acceptable.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 30 • Phone calls will be performed during the study for site staff to remind participants to take 
their injections, answer any questions they may have regarding the injections, and to 
assess AEs. From Weeks 7  to 24, phone calls will be performed on weeks that the 
participants are not seen in the clinic (Weeks 7, 9, 11, 13  to 15, 17  to 19, and 21  to 23). 
After Week 25, phone calls will be performed approximately 4 weeks after each previous 
visit. (If a visit during this period occurs within approximately 4 weeks of the  prior visit, a 
phone call is not necessary.) Phone calls should continue to occur approximately every  
8 weeks after the cessation of treatment, until the E OS visit.  
• Maintenance injections will continue until the last patient enrolled has completed 
52 weeks of treatment . Therefore, the length of maintenance therapy may vary for each 
participant . The maximum duration of treatment for an individual participant is 104 weeks.  
4.2 SCIENTIFIC RATIONALE  FOR STUDY DESIGN   
This study is designed to evaluate BIVV020 in patients with persistent/ chronic primary ITP. 
These patients have failed prior therapies and have few available treatment options. Patients who 
are currently enrolled in study TDR16218 and have responded to sutimlimab will have the option 
of transitioning to this study. In this study, those patients will be able to receive the study drug 
subcutaneously, as opposed to intravenously, whi ch was the case for sutimlimab.  
For pa tients transitioning from sutimlimab to BIVV020, the switch to BIVV020 is expected to 
result in a decreased burden of drug administration while maintaining the same efficacy and risk 
profile as sutimlimab. Both BIVV020 and sutimlimab are monoclonal antibod ies that target the 
same protein, C1s, and inhibit the classical complement pathway. The major difference between 
the 2  molecules is that BIVV020 has mutations that enhance FcRN binding, leading to an 
improved PK profile versus sutimlimab. In addition, BIV V020 demonstrates high affinity and 
specificity for the active form of C1s, whereas sutimlimab binds to both the inactive and active 
forms. BIVV020 has a high affinity (10-9 M) and specificity for the active form of human C1s, 
and is a potent (IC 50 = 10-8 M) and complete (100%) inhibitor of serum classical complement 
pathway activity, but not alternative or lectin pathway activity. The active form of C1s is required 
for the progression of the classical complement pathway. BIVV020 binds only this form, there by 
requiring a lower dose compared to sutimlimab. BIVV020 demonstrates these improvements over 
sutimlimab, while inhibiting the classical complement pathway in effectively the same manner. 
Thus, patients who responded to sutimlimab are expected to have a s imilar response to BIVV020.   
Participant convenience was taken into consideration in the design of this study . At the start of the 
study, the injections will be administered by the study staff . This will ensure that the participants 
are receiving the injec tions appropriately  and will allow them to become familiar with the 
injection procedures . Education on self -administration will also be provided during this time . As 
the study progresses, the injections will be administered to a greater extent at home, whi ch will 
minimize the time spent traveling to the clinic.  However, w hen coming in for clinic visits, the 
participants will self -administer the injections under the supervision of the study staff to ensure 
that the administrations are being performed correct ly.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 31 The maximum duration of treatment for an individual participant is 104 weeks. As of 
29 September 2020, 4 ITP patients have received sutimlimab for approximately  2 years with 
maintained  efficacy and an acceptable safety profile. No new safety concerns associated with 
long-term sutimlimab treatment  have been identified . 
Platelet levels, which constitute the primary efficacy endpoint of the study, are a direct measure of 
disease activity.  
4.2.1  Participant input into design   
Participants were not involved in the design of the study. Nonetheless, this study has a reduced 
visit burden compared to the study from which some  of the participants will be enrolled, 
TDR16218.  
4.3 JUSTIFICATION FOR  DOSE   
The dose level and dosing regimen proposed for this study were derived from modeling and 
simulation based on data  
. A population PK/PD model was developed using   
 and BIVV020 systemic exposure . The initial IV loading 
dose of 50 mg/kg, and the  subsequent maintenance dose  of 600 mg S C once weekly, were  chosen 
to .  
The proposed 600 mg once weekly SC dose is  
 
 
.  
The selected loading dose of 50 mg/kg  
 
. 
4.4 END OF STUDY DEFINIT ION  
The end of the study is defined as the date of the last visit of the last participant in the study.  
A participant is considered to have completed the study if he/she has completed all phases of the 
study including the EOS visit.   
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 32 5 STUDY POPULATION   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 INCLUSION CRITERIA   
Participants are eligible to be included in the study only if all the following criteria apply:  
Age 
I 01. Male and female p articipant s ≥18 years  of age at the time of signing the info rmed consent.  
Type of participant and disease characteristics  
I 02. Confirmed diagnosis of primary ITP ; for participants  who previously received sutimlimab  
in study TDR16218 , a response to sutimlimab must have been obtained, as defined by 
platelet count ≥ 30 × 109/L on 2 visits at least 7 days apart.  
I 03. For participants  who have not previously received sutimlimab : persistent/chronic ITP (ITP 
lasting for ≥ 6 months ) and all the following conditions:  
a) Platelet count ≤30  × 109/L on 2 occasions at least 5 days apart du ring the Screening 
Period ; 
b) Lack of an adequate platelet count response (as defined by maintenance of sustained 
platelet count ≥30 ×  109/L in the absence of bleeding) to at least 2 ITP treat ments , 1 of 
which was a thrombopoietin receptor agonist.  Other ITP  treatments include : IVIg, 
anti-D immunoglobulin, corticosteroids, splenectomy, rituximab,  cyclophosphamide,  
azathioprine, danazol, cyclosporin A, mycophenolate mofeti l, or fostamatinib . 
c) If receiving weekly thrombopoietin receptor agonist dosing, the last dose must have 
been administered ≥7 days before the first dose of BIVV020. If receiving daily 
thrombopoietin receptor agonist dosing, the last dose must have been administered 
≥24 hours before the first dose of BIVV020 . 
d) If applicable, concurrent administra tion of ITP medications ( eg, corticosteroids, IVIg, 
azathioprine, danazol, cyclosporin A, mycophenolate mofetil, or thrombopoietin 
receptor agonists) is acceptable provided the patient has been on a stable dose for at 
least 1  month . See Section  6.8 for additional details . 
e) If previously dosed with rituximab, the last dose of rituximab must have been 
administered at least 12 weeks before the first dose of BIVV020 . 
f) If previously dosed with cyclophosphamide, the last dose of cyclophosphamide must 
have been administered at least 4 weeks be fore the first dose of BIVV020 . 
I 04. Documented vaccinations against encapsulated bacterial pathogens ( Neisseria 
meningitidis , including serogroup B where available, Haemophilus influenzae , and 
Streptococcus pneumoniae ) within 5 years of enrollment , or as specified in Section  8.2.6 . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 33  Contraception  
I 05. All contraceptive s use by men and women should be consistent with local regulations  
regarding the methods of contraception for those participating in clinical studies.  
- Male participants  must be surgically sterile for at least 90 days or agree when sexually 
active with female partners of childbearing potential to use a male condom with 
spermicide for the duration of the study  and for 52 weeks after the last dose of 
BIVV020 . Additionally, sperm donation is not allowed during the study and for 
52 weeks after the last dose of BIVV020.  
- Female participants must be post -menopausal, surgically sterile, or be established on 
(≥3 months prior to screening) and agree to continue to use the same highly effective 
method of birth control in conjunction with male barrier cont raception (eg, male 
condom with spermicide) during their participation in the study  and for 52 weeks after 
the last dose of BIVV020 . Highly effective methods of contrace ption include 
intrauterine device (IUD; Mirena®), established use of oral, implanted, or transdermal 
hormonal method of contraception associated with inhibition of ovulation, bilateral 
tubal ligation, or permanent birth control via the Essure procedure. Pa rticipants who 
practice true abstinence, because of the participant’s lifestyle choice ( ie, the participant 
should not become abstinent just for the purpose of study participation) are exempt  
from contraceptive requirements. Periodic abstinence (eg, calend ar, ovulation, 
symptothermal, postovulation methods) and withdrawal are NOT  acceptable methods 
of contraception.  Additionally, ova donation is not allowed during the study and for 
52 weeks after the last dose of BIVV020.   
Informed Consent  
I 06. Capable of givi ng signed informed consent as described in Appendix 1 ( Section  10.1) of 
the protocol which includes compliance with the requirements and restrictions listed in the 
ICF and in this protocol.  
5.2 EXCLUSION CRITERIA   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditions  
E 01.  Clinically  significant medical history or ongoing chronic illness that would jeopardize the 
safety of the participant or compromise the quality of the data derived from his/her 
participation in the study . 
E 02.  Clinically relevant infection within the month prior to enrol lment . 
E 03.  History of venous or arterial thrombosis within the year prior to enrollment . 
E 04.  Clinical diagnosis of SLE. 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 34 E 05.  Secondary ITP from any cause including lymphoma, chronic lymphocytic leukemia, and 
drug-induced thrombocytopenia . 
E 06.  Positive hepatitis B surface a ntigen (HBsAg) or active HCV infection . For patients with an 
isolated positive anti -HBc antibody, hepatitis B virus ( HBV ) DNA by polymerase chain 
reaction ( PCR ) must be negative at Screening. Patients who have undergone hepatitis C 
antiviral therapy may be  enrolled if they are documented to be HCV RNA negative on at 
least 2 occasions separated by at least 3 months (including 1 RNA test at least 6 months 
after completion of antiviral therapy) and are also HCV RNA negative at Screening . 
E 07.  HIV infection . 
E 08. Positive SARS -CoV-2 molecular test (if coronavirus disease [COVID -19] testing required) . 
Note: Participants switching from sutimlimab may be enrolled even with a positive 
SARS -CoV-2 test, as per the judgement of the Investigator.  
E 09.  Pregnant or lactating wome n. 
E 10.  Eastern Cooperative Oncology Group (ECOG) performance status >2 . 
E 11.  Sensitivity to any of the study interventions, or components thereof, or other allergy that, 
in the opinion of the Investigator, compromises participation in the study . 
Prior/concomitant  therapy  
E 12.  Use of aspirin, nonsteroidal anti -inflammatory drugs (NSAIDS), or anticoagulants within 
1 week prior to enrollment . 
Prior/concurrent clinical study experience  
E 13.  Concurrent treatment with other experimental drugs or participation in another clinical trial 
with any investigational drug (with the exclusion of sutimlimab) within 30 days or 
5 half-lives, whichever is greater, prior to enrollment .  
Diagnostic assessments  
E 14.  Hemoglobin level <10 g/dL . 
E 15.  White blood cells (WBCs) or neutrophil counts outside of normal limits, if considered 
clinically significant by the Investigator . Elevated WBC/absolute neutrophil count (ANC) 
attributed to steroid treatment is acceptable . 
E 16.  Prothrombin time /internationa l normalized ratio  (PT/INR) or activated partial 
thromboplastin time (aPTT) outside of the normal limits, if considered clinically  
significant  by the Investigator . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 35 Other exclusions  
E 17.  Individuals accommodated in an institution because of regulatory or legal order; prisoners 
or participants wh o are legally institutionalized . 
E 18.  Participant s not suitable for participation, whatever the reason, as judged by the 
Investigator, including medical or clinical  conditions, or participants potentially at risk of 
noncompliance to study procedures . 
E 19.  Participants  who are employees of the clinical study site or other individuals directly 
involved in the conduct of the study, or immediate family members of such individ uals 
(in conjunction with Section 1.61 of the International Council for Harmonisation  - Good 
Clinical Practice ( ICH-GCP Ordinance E6) . 
E 20.  Any specific situation during study implementation/course that may r aise ethics 
considerations . 
 
5.3 LIFESTYLE CONSIDERATIONS   
Not applicable.  
5.4 SCREEN FAILURES   
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently enrolled . A minimal set of screen failure information is r equired to ensure 
transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure  reasons , eligibility criteria, 
and any serious adverse event (SAE ). 
Individuals who do not meet the criteria for participation in this study (screen failure s) may be 
rescreened.   
5.5 CRITERIA FOR TEMPORARI LY DELAYING ENROLLMENT/ STUDY INTERVENTION  
ADMINISTRATION   
During  a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency measures are proposed in 
Appendix 9 ( Section  10.9) and should be considered for screening /enrollment/administration of 
study intervention . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 36 6 STUDY INTERVENTION (S) AND CONCOMITANT THERAPY   
Study intervention  is defined as any investigational intervention (s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol.  
6.1 STUDY INTERVENTION(S ) ADMINISTERED   
Table  3 - Overview of study interventions administered   
Intervention label  BIVV020  
Intervention name  BIVV020, humanized anti -C1s monoclonal antibody  
Type  Drug  
Dose formulation  BIVV020 supplied in single use vials containing 750 mg 
(150 mg/mL;  extractable volume of 5 mL ) 
Unit dose strength(s)  750 mg/5  mL 
Dosage level(s)  50 mg/kg IV loading dose, followed by 600 mg SC weekly  
Route of administration  IV loading dose; SC maintenance administration  
Use Experimental  
IMP or NIMP  IMP 
Packaging and labeling  Details are provided in the Pharmacy Manual.  
Current/Former name(s) or alias(es)  Not Applicable  
Table  4 - Arms and associated interventions   
Arm name  BIVV020  
Associated interventions (intervention label[s])  Details are p rovided in the Pharmacy Manual  
An intravenous (IV) loading dose of BIVV020 at 50 mg/kg will be administered on Day 1, and 
will be followed by maintenance doses of 600 mg SC weekly starting on Day 8. For the first 
5 weeks of maintenance therapy, the injections will be performed by the site staff, and participants 
will receive education on self -administration. At Week 6, the participant (or their caregiver) will 
perform the injection under the supervision of the site s taff. Starting at Week 7, the injections will 
be performed by the participants or caregiver at home. See Section  4.1 for additional details 
regarding the location s for IMP administration over the course of the study.  
6.1.1  Intravenous loading dose administration   
• The loading dose of BIVV020 at 50 mg/k g IV will be administered on Day 1.  
• Infusion of the BIVV020 IV preparation should be done using a large volume infusion 
pump.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 37 • Approximately 50 mL of dosing solution and approximately 60 mL of flush will be 
administered. An infusion pump will be programmed to deliver 90 mL at a rate of 
150 mL/hr. Any excess volume over 90 mL will remain in -line to account for IV dead 
space. The total time for infusion will be approximately 45 minutes.  
• The total time of dose preparation (vial puncture) to completion of admin istration may not 
exceed 4 hours.  
• Participants will remain in the clinic for at least 4 hours after the start of IMP 
administration.  
• The administration process is to be documented in the source document worksheet or 
within the administration/dosing logs.  
Further details can be found in the Pharmacy Manual.  
6.1.2  Subcutaneous dose administration   
• The 600 mg SC dose will be administered in 2 injections ; each injection will be  2 mL. 
• Depending the study visit, SC administration my be performed at the site or by the 
patient/caregiver at home. In case of home administration, a Patient Diary should be used 
to record administration details.  
• The recommended injection sites include:  
- Abdomen  (except for the 2  inch [~5 cm ] radius area around the navel). This is the 
preferred location.  
- Top of thighs .  
- Outer area of upper arm (by caregivers only) . 
• The SC injections should be given consecutively , but may be spaced apart by up to 
30 minutes. A different site for each injection should be used (eg different locations on the 
abdomen).  
• The total time of dose preparation (vial puncture) to completion of administration may not 
exceed 4 hours.  
• Participants should be observed for 30 minutes after IMP ad ministration for the first 6  SC 
administrations.  
Further details can be found in the Pharmacy Manual.  
BIVV020 may be supplied at the site or from the Principal Investigator /site/Sponsor to the 
participant via a Sponsor -approved courier company (direct -to-patient [ DTP ]) where allowed by 
local regulations and agreed upon by the participant. The participant/ Investigator can refuse this 
option.  Details are provided in the Pharmacy Manual . 
For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site access, contingency measures are included in 
Appendix  9 (Section  10.9). 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 38 A complete description of BIVV020 and its proper handling will be provided in the Pharmacy  
Manual available to the clinical site.  The appropriate number of kits w ill be dispensed as 
necessary for the periods between visits  (please refer to SoA  Section  1.3). Storage conditions and 
use-by-end date (when required by country regulations) are part of the label text.   
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY  
1. The Investigator  or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention  received . Any discrepancies must be 
reported and resolved before use of t he study intervention . 
2. Only participants enrolled in the study may receive study intervention  and only authorized 
site staff may administer it at clinic visits . All study intervention  stored at the sites  must be 
stored in a secure, environmentally controll ed, and monitored (manual or automated) area 
in accordance with the labeled storage conditions with access limited to the Investigator  
and authorized site staff.  
3. The Investigator , institution, or the head of the medical institution (where applicable) is 
responsible for study intervention  accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation,  and final disposition records).  
Any quality issue noticed w ith the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc) must be promptly notified to the Sponsor . 
Some deficiencies may be recorded through a complaint procedure (see Section  8.3.7 ). 
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the 
Sponsor . In this case, the Investig ator will be responsible for promptly addressing any request 
made by the Sponsor , in order to recall the IMP and eliminate potential hazards .  
Under no circumstances will the Investigator  supply IMP to a third party (except for DTP 
shipment, for which a courier company has been approved by the Sponsor ), allow the IMP to be 
used other than as directed by this clinical trial protocol, or dispose of IMP in any other manner.  
Additional informa tion regarding treatment allocation, preparation and dispensation are available 
in the Pharmacy Manual.  
6.3 MEASURES TO MINIM IZE BIAS: RANDOMIZAT ION AND BLI NDING   
Not applicable.  
6.4 STUDY INTERVENTION C OMPLIANCE   
• IMP accountability:  
- Intervention  units are returned by the pa rticipa nt at each visit. In case of DTP process, 
the intervention units can be returned by the carrier (if defined in the contract) . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 39 - The Investigator  counts the number of  vials, etc, remaining in the returned packs, and 
fills in the Intervention  Log Form . 
- The Investigator  records the dosing information on the appropriate page(s) of t he case 
report form ( CRF ).  
- The monitor in charge of the study then checks the CRF data by comparing them with 
the IMP which he/she has retrieved and intervention  log forms . 
Starting at Week 7, the inject ions will be performed by the patient or caregiver , either at home or 
in the clinic at scheduled visits.  When participants self -administer the study intervention at home, 
they will be provided with a paper diary or e -diary to record their administrations.  
The date and time of each dose administered in the clinic will be recorded in the source 
documents and recorded. The dose of study intervention and study participant identification will 
be confirmed at the time of dosing by a member of the study site staf f other than the person 
administering the study intervention. Deviation(s) from the prescribed dosage regimen should be 
recorded.  
A record of the quantity  of BIVV020 units  dispensed to and administered  by each participant must be 
maintained and reconciled with study interv ention and compliance records. Intervention start and 
stop dates, including dates for intervention delays and/or dose reductions will also be recorded . 
6.5 DOSE MODIFICATION   
Not applicable.  
6.6 CONTINUED ACCESS TO INTERVENTION  AFTER THE END OF TH E STUDY   
Participants will continue to receive BIVV020 until the last participant  enrolled has completed 
52 weeks of treatment . After that time, a long -term extension study may be available for 
participants to continue to receive BIVV020.  If a long -term extension s tudy is available, the 
follow up period for this study may not be applicable or may be modified as per the long -term 
extension study.  
6.7 TREATMENT OF OVERDOSE   
The Sponsor does n ot recommend specific treatment for an overdose , as there is no specific 
antidote. However, any supportive medical treatment may be administered, based on evaluation 
and clinical findings . 
In the event of an overdose, the Investigator should:  
1. Contact the Sponsor  immediately.  
2. Evaluate the participant to determine, in consultation with the Sponsor,  whether study 
intervention should be interrupted or whether the dose should be reduced.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 40 3. Obtain a plasma  sample for PK analysis within 7 days from the date of the last dose of 
study intervention if requested by the Sponsor  (determined on a case -by-case basis).  
4. Document appropriately in the CRF.  
6.8 CONCOMITANT THERAPY   
Any medication or vaccine (including over the counter or prescription medicines, vitamins, and/or 
herbal supplements , and rescue medication ) that the participant is receiving at the time of 
enrollment or receives during the study must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
Vaccinations such as seasonal influenza vaccines and other recommended vaccines and booster 
vaccinations  are permitted as per local standard of care, inve stigator discretion, and local labels.  
Concurrent administration of ITP medications (corticosteroids, IVIg, azathioprine, danazol, 
cyclosporine A, mycophenolate mofetil, or thrombopoietin receptor agonists) is acceptable 
provided the patient has been on a stable dose for at least 1 month.  This applies for both new 
patients and patients who were previously receiving sutimlimab in Study TDR16218.  
Corticosteroids, thrombopoietin receptor agonists, and IVIg are permitted , if the follow 
requirements are met :  
A) Corticosteroids: the first dose of BIVV0 20 may be dosed  only ≥4 days after a steroid pulse 
(single dose of >0.5 mg/kg prednisone equivalent or an increase in prednisone equivalent 
dose from prior  level s) for acute ITP treatment  
B) Thrombopoietin receptor agonis ts: If receiving weekly  thrombopoietin receptor agonist 
dosing, the last dose must have been administered ≥7 days before the first dose of 
BIVV0 20. If receiving daily thrombopoietin receptor agonist dosing, the last dose must 
have been administered ≥24 hou rs before the first dose of BIVV0 20. Thrombopoietin 
receptor  agonists may be restarted by the Investigator if a participant has an insufficient 
response to BIVV020.  
C) Intravenous Ig (IVIg): the first dose of BIVV0 20 must be dosed  ≥1 day after a dose of 
IVIg.  A single dose of IVIg is allowed during the study; additional doses after the first 
dose must be approved by the Sponsor.  
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
6.8.1  Rescue medicine   
Rescue medicines given for acute episodes of thrombocytopenia/bleeding, such as  steroid 
pulse/bolus, thrombopoietin receptor agonists, or platelet transfusion  are allowed  (see a bove for 
guidance on IVIg) . Additionally, increasing the dose of concomitant ITP medications to prevent 
or treat bleeding due to low platelet counts is allow ed and would be considered rescue therapy . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 41 7 DISCONTINUATION  OF STUDY INTERVENTI ON AND 
PARTICIPANT DISCONTINUATION /WITHDRAWAL     
7.1 DISCONTINUATION OF S TUDY INTERVENTION     
7.1.1  Permanent  discontinuation   
In rare instances, it may be necessary for a participant to permanently /definitely  discontinue the 
study intervention. If this occurs, a new participant may be enrolled to repla ce the one who was 
discontinue d, unless the permanent discontinuation was due to a BIVV020 -related adverse reaction or 
safety concern . 
The Investigator/Sponsor must permanently discontinue dosing with BIVV020 in a participant if 
any of the following partic ipant -level stopping rules are met:  
• Pregnancy in a participant while receiving study drug .  
• Change in compliance with inclusion/exclusion criteria that is clinically relevant and 
affects patient’s safety . 
• Intake of non -permitted concomitant medications that might affect participant’s safety or 
study assessments/objectives . 
• An allergic reaction, including an anaphylactic reaction, in association with BIVV020 
administration . 
• SLE or any other immune complex disease . 
• Meningococcal infection . 
• Occurrence of AE s that, in the opinion of Investigator/Sponsor, may jeopardize patient 
safety or data integrity. These include, but are not limited to, abnormal liver tests and 
abnormal QTc, meeting the stopping criteria (see Section  7.1.2 , Section  7.1.3 , Appendix 6, 
Section  10.6). 
• Lack of efficacy (see  Section  7.1.4 ).  
• Participant misses more than 3 consecutive doses of BIVV020 without Investigator 
approval . If a participant misses 3 consecutive doses and the Investigator believes the 
partic ipant should remain in the study, a protocol for BIVV020 re -initiation may be 
considered, in consultation with the Sponsor.  
Handling of participants after permanent  intervention discontinuation  
If study intervention is definitively discontinued, the participant should continue to be followed 
for an additional 22 weeks. The procedures listed for the EOS visit as per the SoA should be 
performed at  the final visit.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 42 All cases of definitive interventi on discontinuation must be recorded by the Investigator in  the 
appropriate pages of the electronic case report form (e CRF ) when considered as confirmed.  
7.1.2  Liver chemistry stopping criteria   
Discontinuation of study intervention for abnormal liver tests is required  by the Investigator when 
a participant meets one of the conditions outlined  in the ALT algorithm in Appendix 6 
(Section  10.6) or in the presence of abnormal liver chemistries not meeting protocol -specified 
stopping rules if the Investigator believes that it is in best interest of the participant.   
7.1.3  QTc stopping criteria   
In the event of prolongation of QTc interval (automatic measurement) ≥500 ms  or increase from 
baseline >60 ms , confirmed by a manual reading by the Investigator  or a physician delegated by 
the Investigator using the Fridericia formula for correcting QT, the participant should be placed 
under supervision in a specialized setting. Investigational medicinal product administration must 
be stopped and appropriate bloo d samples collected. Subsequent ECG monitoring of the 
participant should then be performed on a regular and clinically responsible basis until the QTc 
interval returns to a safe value as determined by the Investigator in agreement with the Sponsor. 
Investi gational medicinal product may be restarted at the discretion of the Investigator 
(in agreement with the Sponsor) once the QTcF returns to a safe value.  
7.1.4  Lack of efficacy (relapse or sustained lack of improvement) stopping criteria   
The study intervention may be discontinued due to a lack of response.  Determination for 
treatment discontinuation in this case will be made by the Investigator and Sponsor.  
7.1.5  Thrombocytosis   
BIVV020 should be discontinued if a participant’s platelet count is >450 × 109/L. BIVV020 may 
be restarted when the platelet count is ≤150 × 109/L. The procedure for BIVV020 re -initiation 
must be discussed with the Sponsor prior to re -dosing.   
7.1.6  Temporary discontinuation   
Temporary intervention discontinuation m ay be considered by the Investigator because of 
suspected AEs  or disruption of the clinical trial due to a regional or national emergency declared 
by a governmental agency (described in Appendix 9 [Section  10.9]). For all temporary 
intervention discontinuations, duration should be recorded  by the Investigator in the appropriate 
pages of the eCRF . 
If a participant is diagnosed with COVID -19, the decision to temporarily discontinue the study 
treatment will be made by the Sponsor and Investigator. Once the patient is fully recovered, the 
decision to restart treatment will be determined by the Investigator and Sponsor.   
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 43 7.2 PARTICIPANT DISCONTI NUATION/ WITHDRAWAL FROM THE STUDY   
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the disc retion of the Investigator  for safety, behavioral  or 
compliance reasons.  This is expected to be uncommon.  
• At the time of discontinuing from the study, if possible, an early discontinuation visit 
should be conducted , following procedures for the E OS visit ( see SoA  [Section  1.3]).  
• If the participant withdraws consent for disclosure of future information, the Sponsor  may 
retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator  must document this in the site study  records.  
If participants no longer wish to take the IMP, they will be encouraged to continue to be followed 
for an additional 22 weeks . The Investigator s should discuss with them key visits to attend. The 
value of all their study data collected during the ir continued involvement will be emphasized as 
important to the public health value of the study.   
Participants who withdraw from the study intervention  should be explicitly asked about the 
contribution of possible AEs to their decision, and any AE informa tion elicited must be 
documented.  
All study withdrawals should be recorded by the Investigator  in the appropriate screens of the 
eCRF and  in the participant ’s medical records. In the medical record, at least the date of the 
withdrawal and the reason should  be documented.  
In addition, a participant  may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention  should be distinguished from withdrawal of consent for 
follow -up visits and from withdrawal of consent for no n-participant  contact follow -up, 
eg, medical record checks. The site should document any case of withdrawal of consent.  
Participants who have withdrawn from the study cannot be reallocated  (retreated) in the study. 
Their study identification  numbers must n ot be reused.   
7.3 LOST TO FOLLOW UP   
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted  by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the particip ant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 44 • Before a participant is deemed lost to follow -up, the Investigator  or designee must make 
every effo rt to regain contact with the participant (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’ s 
medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
• Site personnel, or an independent third party, will attempt to collect the vital status of the 
participant within legal and eth ical boundaries for all participants enrolled . Public sources 
may be searched for vital status information.  If vital status is determined as deceased, this 
will be documented and the participant will not be considered lost to follow -up. Sponsor 
personnel w ill not be involved in any attempts to collect vital status information.  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1 
(Section  10.1).  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 45 8 STUDY ASSESSMENTS AN D PROCEDURES   
• Study procedures and their timing are summarized in the SoA  (Section  1.3). Protocol 
waivers or exemptions are not allowed.  
• Adherence to the study design requirements, including those specified in t he SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator  will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management  or from 
Study TDR16218  (if available ) and obtained before signing of the ICF may be utilized for 
screening purposes provided the procedures met the protocol -specified criteria and were 
performed within the time frame defined in the So A. 
• The maximum amount  of blood collected from each particip ant over the duration of the 
study, including any extra assessments that may be required, will be within a safe limit for 
human clinical trials as recommended by the local Institutional Review Boards and Ethics 
Committees.  Repeat or unscheduled samples may  be taken for safety reasons or for 
technical issues with the samples.  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 9 ( Section  10.9).  
8.1 EFFICACY  ASSESSMENTS   
Planned time points for all efficacy assessments are provided  in the SoA  (Section  1.3). The 
primary efficacy endpoint is determined by platelet counts, which will be assessed by a central 
lab. 
8.2 SAFETY ASSESSMENTS   
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). 
8.2.1  Physical examinations   
• A complete physical examination will include, at a minimum, assessments of the  skin, 
cardiovascular, respiratory, gastrointestinal , and neurological  systems. Height and weight 
will also be measured and recorded.  
• An abbreviated physical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascular  system, and abdomen (liver and spleen) . 
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 46 • Ad-hoc physical exam s may be performed at the discretion of the I nvestigator based on 
any AE reported  by the partic ipant  and need not be limited to the time points listed in the 
SoA. 
8.2.2  Vital signs   
• Temperature , pulse rate, respiratory rate, and blood pressure will be assessed.  
• Blood pressure and  pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.  
• Blood pressure and pulse measurements should be  performed sitting and preceded by at 
least 5 minutes of re st for the participant in a quiet setting without distractions 
(eg, television, cell phones).  
• If possible,  vital signs should be performed prior to the collection of clinical laboratories . 
8.2.3  Electrocardiograms   
• Twleve -lead ECG s will be obtained at the time points defined in the SoA using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals. The readout should include date, time, participant study ID, signature of the 
research physician, and at least 3 complexes for each lead. This printout will be retained at 
the site.  
• If possible,  ECGs should be performed  prior to the collection of cli nical laboratories . 
8.2.4  Clinical safety laboratory assessments   
• See Appendix 2 (Section  10.2) for the list of clinical laboratory tests to be performed and 
the So A (Section  1.3) for the timing and frequency.  These tests will be performed by a 
central lab , except for serum and urine pregnancy tests, which will be performed locally . 
• The Investigator  must review the laboratory report, document this review, and record a ny 
clinically significant  changes occurring during the study as an AE, as per the guidelines in 
Section  10.3.1 . The laboratory reports must be filed with the source documents. Abnormal 
laboratory findings associated with the underlying disease  are not considered clinically 
significant , unless judged by  the Investigator  to be more severe than expected for the 
participant ’s condition.  
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or basel ine 
or are no longer considered clinically significant by the Investigator . 
- If clinically significant  values do not return to normal/baseline within a period of time 
judged reasonable by the Investigator , the etiology should be identified and the 
Sponsor  notified.  
- All protocol -required laboratory tests, as defined in  Appendix 2 ( Section  10.2), must 
be conducted in accordance with the laboratory manual and the SoA  (Section  1.3). 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 47 - If laboratory values from non -protocol specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by the Investigator  (eg, SAE or AE or dose 
modification), then the results must be recorded.  
8.2.4.1  Additional test ing in case of hypersensitivity /allerg ic reaction   
If a participant exhibits signs of a hypersensitivity/allergic reaction during study drug administration, 
the study drug should be stopped immediately, and medical treatment provided, as appropriate.  
In case of a suspected anaphylactic reaction, the following labs may be obtained at the discretion 
of the Investigator, and after discussion with the Sponsor:  
• Approximately 30 to 120 minutes after the start of symptoms: blood draw for antidrug 
antibod ies (ADA), tryptase, IL -6, plasma histamine, CICs, and complement levels (CH50). 
A follow -up tryptase level should be obtained approximately 8 days following the 
reaction.  Further characterization of the ADA response might be performed.  
• 24-hour urine collection for methylhistamine analysis (ideally collection should be started 
within 6 hours of onset of symptoms) . 
8.2.4.2  Additional testing in case of suspected rhabdomyolysis   
If a participant exhibits signs or symptoms which may be indicative of rhabdomyolysis during 
study drug administration, including, but not limited to: muscle pain in the extremi ties or back, 
excessive muscle weakness or trouble moving arms and legs, dark red or brown urine or 
decreased urination, the following labs should be obtained:  
• Serum creatine kinase . 
• Hepatic function panel . 
8.2.5  Pregnancy testing   
Serum and urine pregnancy testing will be performed as per the SoA  (Section  1.3) by lo cal labs.  
8.2.6  Vaccinations against encapsulated bacteria   
In the event a participant  does not have documented vaccination against encapsulated bacterial 
pathogens ( N meningitidis , including serogroup B meningococcus [where available ], H influenzae , 
and S pneumoniae ) within 5 years prior to enrollment, vaccination must be initiated as early as 
possible during the Screening Period.  Vaccination series must be completed as per current regional 
guidelines for patients with persistent complement deficiency, and in accordance with their 
respective labels, as  applicable. Where no regional guidelines are available for patients with 
persistent complement deficiency, vaccinations should includ e meningococcal conjugate, 
meningococcal serogroup B, 13 -valent pneumococcal  (PCV13 ), 23-valent pneumococcal  (PPSV23 ), 
and H influenza  type b vaccines, where available , and administered as per regional guidelines . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 48 All vaccination series should be initiated as early as possible and completed at least 2 weeks prior 
to the first BIVV020 administration. For participants who have not previously received 
pneumococcal vaccines, PCV13 should be given first and PPSV23 at least 8 weeks after the dose 
of PCV13. Participants must be advised that vaccination may not completely prevent infections  
with encapsulated organisms  and that they  should  immediatel y report fevers or other symptoms 
consistent with acute infection to the Investigator.  
Patients who develop symptoms consistent with an infection due to encapsulated bacterial 
pathogens during the study period will have a blood sample collected to test for  confirmation of 
infection.  
8.2.7  Injection  site reactions   
Injection  site reactions should be documented by the Investigator as per the SoA  (Section  1.3). 
These include pain, tenderness, erythema/redness, swelling, induration, and itching. If the 
Investigator considers a n injection site reaction an AE, the appr opriate source form should be 
completed.  
8.2.8  Phone calls   
Phone calls will be performed during the study for site staff to remind participants to take their 
injections, answer any que stions they may have regarding the injections, and to assess AEs. From 
Weeks 7  to 24, phone calls will be performed on weeks that the participants are not seen in the 
clinic (Weeks 7, 9, 11, 13  to15, 17  to 19, and 21  to 23). After Week 25, phone calls will  be 
performed approximately 4 weeks after each previous visit. (If a visit during this period occurs 
within approximately 4 weeks of the prior visit, a phone call is not necessary.) Phone calls should 
continue to occur approximately every 8 weeks after the  cessation of treatment, until the E OS 
visit.  
8.2.9  Participant diary   
At-home IMP administration will be recorded in a participant diary  (paper or e -diary) .  
8.3 ADVERSE EVENTS (AES) , SERIOUS ADVERSE EVEN TS (SAES) AND OTHER 
SAFETY REPORTING   
The definitions of AE s and SAEs can be found in Appendix 3 ( Section  10.3). The definition  of 
AESI  is provided in Section  8.3.6 . 
Adverse event s will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant ’s legally authorized representative).  
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up all AEs (see Section  7). 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 49 The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3). 
8.3.1  Time period and frequency for collecting AE and SAE information   
All AEs (serious or nonserious) will be collected from the signing of the ICF  until the EOS  visit, 
at the time points specified in the SoA ( Section  1.3).  
For participants transitioning from the TDR16218 sutimlimab study, additional considerations and 
requirements for AE/S AE reporting are required . All AEs/SAEs that began during the TDR16218 
study that are ongoing at the EOS visit in TDR16218 and at ICF signature in PDY16894 must be 
reported again during the PDY16894 study screening period in the PDY16894 clinical trial 
database as AEs and as per the SAE reporting procedures outlined in Section  10.3.4 . A follow -up 
SAE report for study TDR16218 should also be submitted for ongoing SAEs when participants 
sign the ICF for PDY16894.   
New AE/SAEs that begin after ICF signature in the PDY16894 s tudy must be reported per the 
standard AE/SAE reporting procedures in Section  10.3. If the AE/SAE occurred within 9 w eeks 
of the last dose of sutimlimab, the event must include an assessment of causality between the 
AE/SAE and sutimlimab . 
All SAEs and AESI  will be recorded and reported to the Sponsor  or designee immediately and 
under no circumstance should this exceed 24  hours, as indicated in Appendix 3 ( Section  10.3). 
The Investigator  will submit any updated SAE and AESI data to the Sponsor  within 24  hours of it 
being available.  
Investigators are not obligated to actively seek information on AEs or SAE s after conclusion of 
the study participa tion. However, if the Investigator  learns of any SAE, including a death, at any 
time after a particip ant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention  or study participation, the Investigator  must promptly 
notify the Sponsor . 
8.3.2  Method of detecting AEs and SAEs   
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method t o inquire about 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs   
After the initial AE/ AESI/ SAE report, the Investigator  is required to proactively follow each 
participant at subsequent visits/contacts. At the pre -specified study end -date, a ll SAEs,  and AE SIs 
(as defined in Section  8.3.6 ), will be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow -up (as defined in Section  7.3). Further information 
on follow -up procedures is provided  in Appendix 3 ( Section  10.3). 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 50 8.3.4  Regulatory reporting req uirements for SAEs   
• Prompt notification by the Investigator  to the Sponsor  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention  under clinical investigation are met.  
• The Sponsor  has a legal responsibility to notify both the local regulat ory authority and 
other regulatory agencies about the safety of a study intervention  under clinical 
investigation. The Sponsor  will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB)/Independent Ethics 
Committees (IEC ), and Investigator s. 
• Serious a dverse events that are considered expected will be specified in the IB.  
• Suspected unexpected serious adverse reactions (SUSAR s) are reported to regulatory 
authorities, Investigators, and IRBs/IECs as follows:  
- For SUSARs that are life -threatening or result in death, reporting is no later than  
7 days after first knowledge by the Sponsor, with all relevant follow -up information 
subsequently reported within an additional 8 days . 
- For SUSARs, other than those that are life -threatening or result in death , reporting is 
no later than 15 days after first knowledge by the Sponsor . 
• An Investigator  who receives an Investigator  safety report describing a n SAE , SUSAR , or 
any other specific safety information ( eg, summary or listing of SAEs) from the Sponsor  
will review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements . It is the responsibility of the Sponsor to assess whether an 
even t meets the criteria for a SUSAR, and therefore, is expedited to regulatory authorities.  
8.3.5  Pregnancy   
• Details of all pregnancies in female participants and  in female partners of male 
participants  will be collected after the start of study interve ntion  and until the end of the 
study.  
• If a pregnancy is reported, the Investigator  will record pregnancy information on the 
appropriate form and submit it to the Sponsor within 24 hours of learning  of the pregnancy  
(after obtaining the appropriate informed  consent for female partners of male participants).  
- Abnormal pregnancy outcomes ( eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs  and will be reported as such . 
• The participant /pregnant female partner  will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow -up information on the participant /pregnant 
female partner  and the neonate and the information will be forwarded to the Sponsor.  
• Any post -study pregnanc y-related SAE considered reasonably related to the study 
intervention by the Investigator will be reported to the Sponsor as described in 
Section  8.3.4 . While the Investigator is not obligated to actively seek this information in 
former study participants /pregnant female partner , he or she may learn of an SAE through 
spontaneous reporting.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 51 • Any female participant who becomes pregnant w hile participating in the study will 
discontinue study intervention . 
8.3.6  Adverse event of special interest   
Adverse event of special interest  
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor ’s product or program, for which ongoing monitoring and immediate notification by the 
Investigator  to the Sponsor is required. Such events may require further  investigation in order to 
characterize and understand them. Adverse events of special interest may be added, modified or 
removed during a study by protocol amendment.  
• Pregnancy  
- Pregnancy occurring in a female participant entered in the study  or in a fema le partner 
of a male participant entered in the study . It will be qualified as an SAE only if it 
fulfills one of the seriousness criteria (see Appendix 3 [ Section  10.3]). 
- In the event of pregnancy in a female participant, IMP should be discontinued.  
- Follow -up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outc ome has been determined . 
• Symptomatic overdose (serious or nonserious) with IMP  
- An overdose (accidental or intentional) with the IMP is an event suspected by the 
Investigator or spontaneously notified by the participant (not based on systematic vials 
or syr inge counts) and defined as at least twice the intended dose within the intended 
therapeutic interval /visits , adjusted according to the tested drug.   
- Infusion : increase of at least 30% of the dose to be administered in the specified 
duration or if the dose  is administered in less than half the recommended duration of 
administration.  
- Of note, asymptomatic overdose is to be reported as a standard AE . 
• QTc ≥500 ms  
• Increase in ALT >3 × ULN (see Appendix 6, Section  10.6) 
• Other project specific AESIs  
- Grade 3 or higher allergic reaction per Common Terminology Criteria for Adverse 
Events (CTCAE ) Version 5.0 grading or an anaphylactic reaction in association with 
BIVV020 administration . 
- Newly diagnosed or potential development of SLE, au toimmune disease or acute flare 
or chronic worse ning of underlying autoimmune disease . 
- Meningococcal infection . 
- Infection due to an encapsulated bacterial organism . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 52 8.3.7  Guidelines for reporting product complaints   
Any defect in the IMP must be reported as soon as possible by the Investigator  to the monitoring 
team that will complete a product complaint form within required timelines.  
Appropriate information ( eg, samples, labels or documents like pictures or photocop ies) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigator  
will assess whether or not the quality issue has to be reported together with an AE or SAE.  
8.4 PHARMACOKINETICS   
8.4.1  Sampling times   
The sampling times for blood collection can be found in the SoA (Section  1.3) 
8.4.2  Sample handling procedure   
Special  procedures for collection, storage, and shipment are provided in the laboratory manual.  
8.4.3  Bioanalytical methods   
Details of bioanalytical methods can be found in the laboratory manual.  
8.4.4  Pharmacokinetic parameters   
Plasma concentrations of BIVV020 will be obtained . This data may be included in a population 
PK analysis.   
Pharmacokinetic samples could be used for testing analytical method performance such as 
comparability and incurred sample reproducibility.  
8.5 GENETICS  AND/OR PHARMACOGENO MICS   
Participants may provide consent for future research to be performed utilizing their sampl es. This 
may include DNA analysis (See Section  8.9 and Section  10.5). 
8.6 BIOMARKERS   
• Collection of biological samples for biomarker re search is also part of this study. The 
following samples for biomarker research are required and will be collected from all 
participants in this study as specified in the SoA ( Section  1.3): 
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 53 • Samples will be tested to evaluate their association with the observed clinical responses . 
• In addition, samples will be stored and analysis may be performed on additional 
biomark ers related to the complement pathway to evaluate their association with observed 
clinical responses . 
• Samples may be used for research to develop methods, assays, prognostics and/or 
companion diagnostics related to the mechanism of action of BIVV020 . 
• Samples collected for biomarker analyses and their derivatives will be stored for a period 
of up to  5 years after last patient last visit for potential re -analyses.   
8.7 IMMUNOGENICITY ASSES SMENTS   
Antibodies to BIVV020  will be evaluated in plasma  samples collected from all participants 
according to the SoA  (Section  1.3). Additionally, plasma  samples should also be collected at the 
final visit from participants who discontinued study intervention or were withdrawn from the 
study. These samples will be t ested by the Sponsor or Sponsor ’s designee.  
Plasma samples will be screened for antibodies binding to BIVV020  and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to BIVV020  and/or further characterize the immunogenicity of BIVV020 . 
The detection and characterization of antibodies to  BIVV020  will be performed using a validated 
assay method by or under the supervision of the Sponsor. All samples collected for detection of 
antibodies to study intervention  will also be evaluated for BIVV020 plasma  concentration to 
enable interpretation of the antibody data. Antibodies may be further characterized and/or 
evaluated for their ability to neutralize the activity of the study inter vention(s).  Samples may be 
stored for a maximum of 5 years (or according to local regulations) following the last participant’s 
last visit , at a facility selected by the Sponsor to enable further analysis of immune responses to 
BIVV020 . 
8.8 HEALTH ECONOMICS OR MEDICAL RESOURCE UTILIZATION AND HEAL TH 
ECONOMICS   
Health economics or medical resource utilization and health economics  parameters are not 
evaluated in this study.  
8.9 USE OF BIOLOGICAL SAMPLES A ND DATA FOR FUTURE R ESEARCH   
Future research may help further the understanding of disease subtypes, disease biology, related 
conditions, drug response and t oxicity, and can help identify new drug targets or biomarkers that 
predict participant response to treatment. Therefore, data and biological samples will be stored 
and used for future research when consented to by participants (see  Section  10.1.3 ) unless 
prohibited by local laws or IRBs/IECs (in such case, consent for future use of sample will not be 
included in the local ICF ).  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 54 For par ticipants who consent to the storage and use of their data and remaining and/or extra 
clinical samples, data and samples may be used after the study ends for future research related 
either to the drug, the mechanism of action , and the disease or its associ ated conditions. Such 
research may include, but is not limited to, performing assessments on DNA, RNA, proteins or 
metabolites.  If future research on genetic material is performed, this will also be limited to the 
purpose of addressing research questions r elated to the drug, the mechanism of action, the disease 
or its associated conditions.  
In the event future research is conducted for other purposes, the study participants will be 
informed of those purposes and will be given means to object to those resear ch projects.  
Data and samples will be used in compliance with the information provided to participants in the 
ICF Part 2 (future research).  
All study participant data and samples will be coded such that no participant direct identifiers will 
be linked to them. Coded data and samples may be transferred to a Sponsor site (or a 
subcontractor site), which may be located outside of the country where the study is conducted. 
The Sponsor adopt s safeguards for protecting participant  confidentiality and personal dat a 
(see Section  10.1.4 ). 
The samples will be stored for a maximum of 15 years  after the end of the study. Any samples 
remaining at the end of retention period  will be destroyed. If a participant requests destruction of 
his/her samples before the end of the retention period , the Investigator must notify the Sponsor 
(or its contract organization) in writing. In such case, samples will be de stroyed and related coded 
data will be anonymized unless otherwise required by applicable laws.  
Study participant coded data will be stored for future research for up to 25 years after the end of 
the study. If data are still considered of important scienti fic value after this period, coded data 
already available will be anonymized unless otherwise required by applicable laws (the same will 
apply to the data of a study participant who has requested the destruction of his/her samples).  
A participant’s coded d ata sets provided to researchers for a specific research project will be 
available to the researchers  for a maximum of 2 years after the  end of their specific project (end of 
project is defined by publication of the results or finalization of the  future  research project  report).  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 55 9 STATISTICAL CONSIDER ATIONS     
9.1 SAMPLE SIZE DETERMIN ATION   
Approximately 12 participants will be enrolled  to receive the  study intervention . Since there is no 
statistical hypothesis to be tested, the sample size is not determined statistically.  
9.2 POPULATIONS FOR ANALYSES   
The following populations for analyses are defined:  
Table  5 - Populations for analyses   
Population  Description  
Screened  All participants who signed the informed consent form ( ICF). 
Enrolled  All participants from the screened population  who receive at least 1 dose (full or 
partial) of study intervention . 
Intention to Treat (ITT)  All participants who receive at least 1 dose (full or partial) of study intervention.  
Safety  All participants who receive at least 1 dose (full or partial) of study intervention.  
Pharmacokinetic (PK)  All participants who receive at least 1 dose (full o r partial) of study intervention with 
sufficient sample data.  
Pharmacodynamic (PD)  All participants who receive at least 1 dose (full or partial) of study intervention with 
sufficient sample data to assess PD parameters.  
PK/PD  All enrolled participants in the PK population with at  least 1 time -matched PK/PD 
parameter.  
 
9.3 STATISTICAL ANALYSES   
The Statistical Analysis Plan (SAP ) will include a more technical and detailed description of the 
statistical analyses described in this section. This section is a summary of the planned statistical 
analyses of the most important endpoints including pri mary and key secondary endpoints . 
9.3.1  General considerations   
• Common definitions of baseline .  
• General methods (eg, how the continuous variables will be summarized) . 
The baseline value is defined as the last non -missing assessment before the first dose of study 
drug.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 56 Unless otherwise specified, analyses will be performed  based on the populations described above ; 
safety analysis will be performed based on the safety pop ulation; PK, PD , and PK/PD analyses 
will be performed using the respective populations as defined in Section  9.2. 
The observation period will be divided into 3 segments:  
• The pre-treatment period is defined as the p eriod  from enrollment up to the first dose of 
study intervention.  Demographics, baseline disease characteristics, medical history, and 
prior therapy including prior ITP therapy use will be summarized based on data collected 
in this period.   
• The treatment -emergent (TE) period  (or the study treatment period)  for efficacy  and 
exposure analysis is defined as the period from the first study intervention  administration 
to the last study intervention  administration + 7 days.  
• The safety analysis  period  is defined as the period from the first study intervention 
administration to the EOS visit . Safety summaries will be based on this period.  
9.3.2  Primary endpoint   
The primary endpoint is described in Section  3. 
The num ber and proportion of participants meeting the responder criteria will be presented; the 
95% confidence interval of the proportion of responders will be estimated using Clopper -Pearson 
method.  Missing data will not be imputed in the statistical analysis. If a patient discontinues study 
treatment prior to Week 3, the patient will be considered as a non -responder . If a patient 
discontinues the study treatment after Week 3 and prior to Week 24, his  or her  responder status 
will be assessed using the available d ata between Week 3 and Week 24.  
9.3.3  Secondary endpoints   
The secondary endpoints are described in Section  3.  
For the continuous secondary endpoints (clinical and laboratory parameters, PK parameters), 
summary statistics by visit including sample size, mean and standard deviation, median, minimum 
and maximum will be presented for the actual value and the change from baseline , if applicable .  
For the time -to-event endpoint (ie, time to first platelet response), Kaplan -Meier method will be 
used to estimate the proportion of participants with response a t different study day, and the 
median time to response. Participants with no response will be censored at the date of the last 
platelet count assessment.  
For the responder endpoint (ie, participants who did not require rescue therapy for an acute 
thromboc ytopenia episode after Week 3), the number and proportion of such participants will be 
presented, along with the 95% confidence interval of the proportion estimated using 
Clopper -Pearson method.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 57 9.3.4  Exploratory endpoints   
9.3.5  Safety  analys is  
9.3.5.1  Adverse events   
Treatment -emergent adverse events ( TEAEs ) are AEs that develop after the first study drug 
administration in the safety analysis period. All AEs in the study include TEAEs and AEs that 
develop prior to the first study drug administration and continue into the safety analysis period. 
All deaths in  the study will be reported.   
An overall summary  table will be provided with numbers and proportions of participants with at 
least one of the following events (not limited to):  
• TEAE  and TESAE  
• Related TEAE  and TESAE   
• TEAE Grade 3 or higher  
• TEAESI  
• TEAE infection of Grade 3 or higher  and TESAE infection  
• Discontinuation of study treatment and/or withdrawal from study due to a TEAE  
• Death  
Additional summaries, including but not limited to, the incidence of TEAEs and TESAEs by 
system organ class (SOC ) and preferred term, and by relationship to study intervention.  
9.3.5.2  Laboratory variables  and vital signs   
For laboratory parameters, potentially clinically significant abnormality (PCSA ) analyses will be 
performed based on the PCSA list currently in effect at Sanofi at the time of the database  lock.   
For vital sign s, descriptive statistics for results and changes from baseline will be provided for 
each visit during the safety analysis period. the number and percentage of participants with 
potentially clinically significant vital signs will be p rovided.  
9.3.6  Other analys is  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 9 ( Section  10.9).  
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 58 9.4 INTERIM ANALYS ES   
An interim analysis will be performed when approximately 12 patients have each been treat ed for 
15 weeks.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 59 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS   
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS   
10.1.1  Regulatory and ethical considerations   
• This study will be conducted in accordance with the protocol and with the following:  
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsink i (2013)  and the applicable amendments and Council for 
International Organizations of Medical Sciences (CIOMS) International Ethi cal 
Guidelines . 
- Applicable ICH GCP Guidelines . 
- Applicable laws and regulations  (eg, data protection law as Gene ral Data Protection 
Regulation [ GDPR ]). 
• The protocol, protocol amendments,  ICF, Investigator Brochure, and other relevant 
documents ( eg, advertisements) must be submitted to an IRB/IEC by the Investigator  and 
reviewed and approved by  the IRB/IEC  before the study is initiated.  
• Any amendments to the protocol will require  IRB/IEC a pproval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to  initiation except for changes necessary to eliminate an immediate hazard 
to study participants.  
• The Investigator  will be responsible for the following:  
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC .  
- Determining whether an incidental finding  (as per Sanofi policy)  should be returned to 
a participant and, if it meets the appropriate criteria, to ensure the finding is  returned 
(an incidental finding is a previously undiagnosed medical condition that is discovered 
unintentionally and is unrelated to the aims of the study for which the tests are being 
performed). The following should be considered when determining the re turn of an 
incidental finding:  
- The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so , designated by the participant) is consistent with all 
applicable national, state, or regional laws and regulat ions in the country where the 
study is being conducted, and  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 60 - The finding reveals a substantial risk of a serious health condition or has 
reproductive importance, AND has analytical validity, AND has clinical validity.  
- The participant in a clinical study ha s the right to opt out of being notified by the 
Investigator of such incidental findings. In the event that the participant has opted 
out of being notified and the finding has consequences for other individuals, 
eg, the finding relates to a communicable di sease, Investigators should seek 
independent ethical advice before determining next steps . 
- In case the participant  has decided to opt out, the Investigator must record in the 
site medical files that she/he does not want to know about such findings.  
- Notifyi ng the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures . 
- Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014  for clinical studies (if applicable) , European Medical Device Regulation 
2017/745  for clinical device research (if applicable) , and all other applicable local 
regulations . 
As applicable, according to Directive 2001/20/EC, the Sponsor will be responsible fo r obtaining 
approval from the Competent Authorities of the EU Member States and /or Ethics Committees, as 
appropriate, for any am endments to the clinical trial that are deemed as “substantial” ( ie, changes 
which are likely to have a significant impact on th e safety or physical or mental integrity of the 
clinical trial participants or on the scientific value of the trial) prior to their implementation.  
10.1.2  Financial disclosure   
Investiga tors and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3  Informed c onsent process   
• The Investigator or his/her representative will explain the nature of the study to the 
participants  and answer all questions regarding the study, including what happens to the 
participant when his/her participation ends.  
• Participants must be informed that their participation is voluntary. Participants  will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 
50, local regulations, ICH guidelines, Privacy and Data Protection requirements including 
those o f the GDPR and of the French law, Health Insurance Portability and Accountability 
Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before th e participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 61 • In case of ICF amendment while the participants are still included in the study, they must 
be re-consented to the most current version of the ICF(s).Where participants are not in the 
study anymore, teams in charge of the amendment must define if those participants must 
or not re -consent or be informed of the amendment (eg, if the processing of pe rsonal data 
is modified, if the Sponsor changes, etc).  
• A copy of the ICF(s) must be provided to the participant .  
Participants who are rescreened are required to sign a new ICF.  
The ICF contains 2 separate sections that addresses the use for research of pa rticipants’ data 
and/or samples (remaining mandatory ones or new extra samples collected for optional research). 
Optional exploratory research must be detailed in the section “Optional tests/procedures” and 
future research is to be defined in Core Study In formed Consent Form (CSICF) Part 2. Each 
option is subject to an independent consent and must be confirmed by ticking a checkbox in 
CSICF Part 3. The Investigator or authorized designee will explain to each participant the 
objectives of the exploratory res earch and why data and samples are important for future research. 
Participants will be told that they are free to refuse to participate and may withdraw their consent 
at any time and for any reason during the storage period.  
For a regional or national emer gency declared by a governmental agency, contingency measures 
are included in Appendix 9 (Section  10.9).  
10.1.4  Data p rotection   
All personal data collected and/or processed in relation to this study will be handled in 
compl iance with all applicable Privacy & Data Protection laws and regulations, including the 
GDPR. The study Sponsor is the Sanofi company responsible for ensuring compliance with this 
matter, when processing data from any individual who may be included in the Sanofi databases, 
including Investigators, nurses, experts, service providers, Ethics Committee members, etc .  
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor takes all appropriate measures to safeguard and prevent access to this 
data by any unauthorized third party.  
Protection of participant data  
Data collected must be adequate, relevant and not excessive, in relation to the purposes for which 
they are collected. Each category of data must b e properly justified and in line with the study 
objective.  
Participant race and ethnicity will be collected in this study because they are required by 
regulatory agencies (eg, on African American population for the FDA or on Japanese population 
for the Pha rmaceuticals and Medical Devices Agency in Japan). They will not be collected in the 
countries where this is prohibited by local regulation.  
• Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor or its service providers will be identifiable only 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 62 by the unique identifier; participant names or any information whic h would make the 
participant identifiable will not be transferred to the Sponsor.  
• The participant must be informed that his/her personal study -related data will be used by 
the Sponsor in accordance with applicable data protection laws. The level of disclo sure 
must also be explained to the participant as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponso r, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
• Participants must be informed that their study -related data will be used for the whole “drug 
development program”, ie, for this trial as well as for the following steps neces sary for the 
development of the investigational product, including to support negotiations with payers 
and publication of results.  
Protection of data related to professionals  involved in the study  
• Personal data (eg, contact details, affiliation(s) details , job title and related professional 
information, role in the study, professional resume, training records) are necessary to 
allow Sanofi to manage involvement in the study and/or the related contractual or 
pre-contractual relationship. They may be communi cated to any company of the Sanofi 
group (“Sanofi”) or to Sanofi  service providers, where needed.  
• Personal data can be processed for other studies and projects. At any time, objection to 
processing can be made  by contacting the Sanofi Data Protection Offic er (link available at 
Sanofi.com).   
• In case of refusal to the processing of personal data by or on behalf of Sanofi, it will be 
impossible to involve  the professionals in any Sanofi study. In case the professionals have 
already been involved in a Sanofi st udy, they will not be able to object to the processing of 
their personal data as long as they are required to be processed by applicable regulations. 
The same rule applies in case the professionals are listed on a regulatory agencies 
disqualification list.  
• Personal data can be communicated  to the following recipients:  
- Personnel within Sanofi or partners or service providers involved in the study ,  
- Judicial, administrative and regulatory authorities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the 
framework of judicial or administrative procedures. Contact details and identity may 
also be published on public websites in the interest of scientific research transparency . 
• Personal data may be tran sferred towards entities located outside the Economic European 
Area, in countries where the legislation does not necessarily offer the same level of data 
protection or in countries  not recognized by the European Commission as offering an 
adequate level of protection. Those transfers are safeguarded by Sanofi in accordance with 
the requirement of European law including, notably:  
- The standard contractual clauses of the European Commission for transfers towards 
our partners and service providers,  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 63 - Sanofi’s Bin ding Corporate Rules for intra -group transfers.  
• Professionals have the possibility to lodge a complaint with Sanofi leading Supervisory 
Authority, the “Commission Nationale de l’Informatique et des Libertés” (CNIL) or with 
any competent local regulatory a uthority.  
• Personal data of professionals will be retained by Sanofi for up to thirty (30) years, unless 
further retention is required by applicable regulations.  
• In order to facilitate the maintenance of Investigators personal data, especially if they 
contribute to studies sponsored by several pharmaceuticals companies, Sanofi participates 
in the Shared Investigator Platform (SIP) and in the TransCelerate  Investiga tor Registry 
(IR) project ( https://transceleratebiopharmainc.com/initiatives/investigator -registry/ ). 
Therefore, personal data will be securely shared by Sanofi with other pha rmaceutical 
company members of the TransCelerate  project. This sharing allows Inv estigators to keep 
their data up -to-date once for all across pharmaceutical companies participating in the 
project, with the right to object to the transfer of the data to the TransCelerate  project.  
• Professionals have the right to request the access to an d the rectification of their personal 
data, as well as their erasure (where applicable) by contacting the Sanofi Data Protection 
Officer: Sanofi DPO - 54 rue La Boétie - 75008 PARIS - France (to contact Sanofi by 
email, visit https://www.sanofi.com/en/our -responsibility/sanofi -global -privacy -
policy/contact ). 
10.1.5  Review Committees   
Study  Monitoring Committee  
The Study Monitoring Committee (SMC) will comprise at least 2 investigators participating in the 
study as well as Sponsor representatives from clinical and pharmacovigilance functions. The SMC 
will meet quarterly to review safety data and can make recommendations about early study 
closure or changes to the conduct of the study.   
Safety Management Team  
Participant safety will be continuously monitored by the Sponsor’s internal safety team, which 
includes safety signal detection, comprehensive cross -functional characterization , and monitoring 
of the product safety profile at any time  during the study as per the Internal Sponsor S afety 
Management Team (SMT)  charter (BTD -010790).  
All safety data collected will be summarized and reviewed by the  Sponsor’s internal safety team 
for agreement of next steps.  
Based on the review of safety data, enrollment in the study may be paused or the study may be 
stoppe d. 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 64 10.1.6  Dissemina tion of clinical study d ata  
Study participants  
Sanofi shares information about clinical trials a nd results on publicly accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments established by pharmaceutical industry associations.  These 
websites include  clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as well as 
some national registries.  
In addition, results from clinical trials in patients are required to be submitted to peer -reviewed 
journals following internal company review for accuracy, fair balance , and intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their request to 
clinicalstudydatarequest.com.  
Indivi dual participant data and supporting clinical documents are available for request at 
clinicalstudydatarequest.com. While making information available we continue to protect the 
privacy of participants in our clinical trials.  Details on data sharing criteri a and process for 
requesting access can be found at this web address: clinicalstudydatarequest.com . 
Professionals involved in the study or in the drug development program  
Sanofi may publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, made to healthcare organizations and 
professionals and/or any direct or indirect advantages and/or any related information or document 
if required by applicable law, by regulation or by a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and 
Healthcare Organisations”.  
10.1.7  Data q uality assurance   
• All participant data relating to the study will be recorded on printed or eCRF unless 
transmitted to the Sponsor or designee electronically ( eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurat e and correct by 
physically or electronically signing the eCRF.  
• Guidance on completion of CRFs will be provided . 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to s ource data documents.  
• Monitoring details describing strategy ( eg, risk -based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, includin g handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in separate study documents.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 65 • The Sponsor or designee is responsible for the data management of this study including 
quality checking of the d ata. 
• The Sponsor assumes accountability for actions delegated to other individuals 
(eg, Contract Research Organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator for 25 year s after the signature of the final study 
report unless local regulations or institutional policies require a longer retention period. No 
records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be tra nsferred to another location or party without written 
notification to the Sponsor . 
10.1.8  Source documents   
• Source documents provide evidence for the existence of the participant and sub stantiate 
the integrity of the data collected. Source documents are filed at the Investigator ’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepanci es must be 
explained. The Investigator  may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete , and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable reg ulatory requirements.  
10.1.9  Study and site start and closure   
First act of recruitment  
The study start date is the date on which  the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open  and will be the study start date.  
Study/Site termination  
The Sponsor  or designee reserves the right to close the study site or terminate t he study at any 
time for any reason at the sole discretion of the Sponsor . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit  has been performed.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 66 The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for study termination by the Sponsor, as well as reasons fo r the early closure of a study 
site by the Sponsor or Investigator may include but are not limited to:  
• For study termination:  
- Information on the product leads to doubt as to the benefit/risk ratio . 
- Discontinuation of further study intervention development . 
• For site termination:  
- Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines . 
- Inadequate or no recruitment (evaluated after a reasonable amount of t ime) of 
participants by the Investigator . 
- Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The Investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
Study hold  
A dosing and enrollment hold will occur if there is >1 participant with a Grade 4 or higher TEAE, 
unless determined to be clearly unrelated to IMP or attributable to an underlying pre -existing 
disease or condition. The  hold may be lifted if the benefit/risk ratio of the study is still deemed to 
be favorable by the S tudy Monitoring  Committee  and applicable regulatory and ethical bodies.  
10.1.10  Publication p olicy   
• The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator  agrees to submit all manuscripts or abstracts to the Sponsor  
before submission. This allows the Sponsor  to protect proprietary  information and to 
provide comments.  
• The Sponsor  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor  will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator  will be designated by mutual agreement.  
• Authorship will be determined by mutual agreement and in li ne with International 
Committee of Medical Journal Editors authorship requirements.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 67 10.2 APPENDIX 2: CLINICAL LABORATORY TESTS   
• The tests detailed in Table  6 will be performed by the central laboratory  unless otherwise 
specified.  
• Local laboratory results are only required in the event that the centra l laboratory results are 
not available in time for either study intervention  administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central analysis 
is obtained at the same time.  Additionally, if the local laboratory results are used to make 
either a study intervention  decisio n or response evaluation, the results must be recorded . 
• Additional tests may be performed at any time during the study as deemed  necessary by 
the Investigator or required  by local regulations . 
• Pregnancy testing ( serum  and urine) will be performed locally . 
• SARS -CoV -2 testing, if applicable , will be performed through the central lab .  
Table  6 - Protocol -required laboratory tests   
 
Laboratory tests  Parameters  
Hematology   
 Platelet count  
 Red blood cell (RBC) count  
 Hemoglobin  
 Hematocrit  
 RBC indices  (at minimum) : 
 Mean corpuscular volume ( MCV ) 
 Mean corpuscular hemoglobin (MCH ) 
 White blood cell (WBC) count with differential : 
 WBC  
Neutrophils  
 Lymphocytes  
 Monocytes  
 Eosinophils  
 Basophils  
Clinical chemistry   
 Blood urea nitrogen (BUN)  
 Creatinine  
 Glucose (non-fasting ) 
 Potassium  
 Sodium  
 Calcium  
 Aspartate aminotransferase (AST)/ Serum glutamic -oxaloacetic transaminase  (SGOT)  
 Alanine aminotransferase ( ALT)/Serum glutamic -pyruvic transaminase (SGPT)  
 Alkaline phosphatasea 
 Total and direct bilirubin  
 Total protein  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 68 Laboratory tests  Parameters  
Coagulation   
 Prothrombin time ( PT)/international normalized ratio ( INR) 
 Activated partial thromboplastin time ( aPTT ) 
SLE panel   
 Antinuclear antibody ( ANA) 
Double -stranded DNA ( dsDNA ) 
Anti-La/SSB antibody (SS -B) 
Anti-Ribonucleoprotein antibody (RNP)  
Anti-Smith antibody (Sm)  
Anti-Ro/SSA antibody (SS -A)  
Anti-Scleroderma antibody (SCL -70)  
Anti-Chromatin antibody  
Anti-Jo-1 antibody  
Anti-Centromere B antibody  
Circulating immune complexes (CIC ) 
Other   
 Serum creatine kinase (CK) (at Screening only)  
Follicle -stimulating hormone ( FSH) (at Screening only, if indicated; see Section  10.4.1 ) 
 CH50  
Routine urinalysis  • Specific gravity  
• pH, glucose, protein, blood , ketones , bilirubin, urobilinogen, nitrite, leukocyte 
esterase by dipstick  
• Microscopic examination (if blood or protein is abnormal)  
Pregnancy testing  • Serum or highly sensitive urine  human chorionic gonadotropin (hCG) pregnancy 
test (as needed for women of childbearing potential)  will be performed locally  
Other screening tests  • FSH (as needed in women of non -childbearing potential only)  
• Serology ( human immunodeficiency virus [ HIV] antibody, hepatitis B surface 
antigen [HBsAg],  hepatitis B core antibody [HBcAb]  immunoglobulin [Ig] G and 
IgM, and hepatitis C virus antibody ) 
• Severe acute respiratory syndrome coronavirus 2 ( SARS -CoV-2) molecular test (if 
applicable)   
NOTES:  
a If alkaline phosphatase is elevated, consider fractionating.  
Investigators must document their review of each laboratory safety report.  
10.3 APPENDIX 3: AES AND  SAES:  DEFINITIONS AND PRO CEDURES FOR RECORDIN G, 
EVALUATING, FOLLOW -UP, AND REPORTING   
10.3.1  Definition  of AE  
AE definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention , whether or not considered related 
to the study intervention . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 69 • NOTE: An AE can therefore be any unfavorable and uni ntended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention . 
Definition of unsolicited and solicited AE  
• An unsolicited adverse event is an adverse event that was  not solicited using a participant 
diary and that is communicated by a participant who has signed the informed consent. 
Unsolicited AEs include serious and non -serious AEs.  
• Potential unsolicited AEs may be medically attended (ie, symptoms or illnesses requ iring a 
hospitalisation, or emergency room visit, or visit to/by a health care provider). The 
participants  will be instructed to contact the site as soon as possible to report medically 
attended event(s), as well as any events that, though not medically at tended, are of the 
participant’s  concern . Detailed information about reported unsolicited AEs will be 
collected by qualified site personnel and documented in the participant’s records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by the 
participant  will be collected during interview with the participant  and by review of 
available medical records at the next visit.  
• Solicited AEs are predefined local (at the i njection site ) and systemic events for which the 
participant is specifically questioned.  
Events  meeting  the AE definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( eg, ECG, radiologica l scans, vital signs measurements), 
including those that worsen from baseline, that are considered clinically significant in the 
judgement of the Investigator and  are not related to pro gression of underlying disease . For 
example : 
- Symptomatic and/or  
- Requiring either corrective treatment or consultation, and/or  
- Leading to IMP discontinuation or modification of dosing, and/or  
- Fulfilling a seriousness criterion, and/or  
- Defined as an AESI  
• Exacerbation of a chronic or intermittent pre -existing condition  including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention  administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant medication.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 70 • “Lack of efficacy ” or “failure of expected pharmacological action ” per se will not be  
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfi ll the definition of an AE or SAE.  
• The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfi ll the definition of an AE or SAE.  
Events NOT meeting the AE definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
Investigator  to be more severe than expected for the participant’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
• Medical or surgical procedure ( eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medic al occurrence did not occur (social and/or 
convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen . 
10.3.2  Definition of  SAE  
An SAE is defined as any adverse event that, at any dose:  
a) Results in death  
b) Is life -threatening  
The term “ life-threatening ” in the definition of “serious ” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c) Requires inpatient  hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been admitted  (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment  that would not have been appropriate in the physi cian’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or  was necessary, the 
AE should be considered serious.  
Hospitalization for elective treatment  of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 71 d) Results in persistent  or significant  disability/incapacity  
- The term disabilit y means a substantial disruption of a person’s ability to conduct 
normal life functions.  
- This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma ( eg, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e) Is a congenital  anomaly/birth defect  
f) Other situations : 
- Medical or scientific judgment should be exercised  by the Investigator in deciding 
whether SAE reporting is appropriate in other situations such as significant  
medical events that may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
- Note: The following list of medically important events is intended to serve as a 
guideline for determining which condition has to be considered as a medically 
important event. The lis t is not intended to be exhaustive:  
- Intensive treatment in an emergency room or at home for:  
- Allergic bronchospasm   
- Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow 
aplasia, myelodysplasia, pancytopenia, etc)  
- Convulsions ( seizures, epilepsy, epileptic fit, absence, etc)  
- Development of drug dependence or drug abuse  
- Suicide attempt or any event suggestive of suicidality  
- Syncope, loss of consciousness (except if documented as a consequence of 
blood sampling)  
- Bullous cutane ous eruptions   
- Cancers diagnosed during the study or aggravated during the study  (if judged 
as unusual or significant by the Investigator)  
- Chronic neurodegenerative diseases (newly diagnosed) or aggravated during 
the study  (if judged unusual or significant  by the Investigator) . 
10.3.3  Recording and follow -up of AE and/or SAE   
AE and SAE r ecording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all  
documentation ( eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 72 • The Investigator  will then record all relevant AE/SAE information.  
• It is not acceptable for the Investigator  to send photocopies of the participa nt’s medical 
records to the Sponsor’s representative  in lieu of completion of the required form.  
• There may be instances when copies of medical records for certain cases are requested by 
the Sponsor’s representative . In this case, all participant identifier s, with the exception of 
the participant number, will be redacted on the copies of the medical records before 
submission to the Sponsor’s representative.  
• The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or o ther clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity  
Adverse events will be graded according NCI -CTCAE v5 and classified by SOC/preferred term 
according the last available version of the Medical Dictionary for Regulatory Activities 
(MedDRA ) dictionary.  
For AEs not included in the NCI CTCAE, the Investigator will be required to assess the intensity  
of the adverse drug/biologic experience using the CTCAE general guideline:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;  
intervention not indicated.  
• Grade 2: Moderate; minim al, local or noninvasive intervention indicated; limiting age  
appropriate instrumental activities of daily living. Instrumental activities of daily living  
refer to preparing meals, shopping for groceries or clothes, using the telephone, managing  
money, etc . 
• Grade 3: Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
activities of daily living. Self -care activities of daily living refer to bathing, dressing and  
undressing, feeding self, using the toilet, taking medications and not bedridden.  
• Grade 4: Life -threatening consequences; urgent intervention indicated.  
• Grade 5: Death related to AE.  
An event is defined as “ serious ” when it meets at least 1 of  the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.  
Assessment of causality  
• The Investigator  is obligated to assess the relationship between study intervention  and 
each occurrence of each AE/SAE.  
• A “reasonable  possibility ” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled 
out. 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 73 • The Investigator  will use clinical judgment to determine the relationship.  
• Alter native causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention  
administration will be considered and investigated.  
• The Investigator  will also consult the I B and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE, the Investigator  must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator  has minimal 
information to include in the initial report. However, it is very important that the 
Investigator  always make an assessment of causality for every event before the initial 
transmission of the SAE data.  
• The Investigator  may change his/her opinion of causality in light of follow -up information 
and send a n SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluatio ns as medically indicated or as requested by the Sponsor’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or con sultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the Investigator  will provide the Sponsor  with a copy of any post -mortem findings 
including histopathology . 
• New  or updated information will be recorded in the originally submitted documents . 
• The Investigator  will submit any updated SAE data to the Sponsor  within 24 hours of 
receipt of the information.  
10.3.4  Reporting of SAE s  
SAE reporting to the Sponsor  via an electronic data collection tool  
• The primary mechanism for reporting an SAE to  the Sponsor’s representative  will be the 
electronic data collec tion tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data col lection 
tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes availabl e. 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 74 • After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a paper SAE form (see next section) or 
to the  Sponsor’s representative  by telephone.  
SAE reporting to the Spon sor via paper data collection tool  
• Facsimile transmission of the SAE paper data collection tool  is the preferred method to 
transmit this information to the Sponsor’s representative.  
• In rare circumstances and in the absence of facsimile equipment, notificat ion by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service.  
• Initial notification via telephone does not replace the need for the Investigator  to complete 
and sign the SAE data collection tool within the designated reporting time frames . 
10.4 APPENDIX 4: CONTRACEPTIVE AND BARRIER GUIDANCE   
10.4.1  Definitions   
A woman is considered women of childbearing potential ( WOCBP ) (fertile) from the time of 
menarche until becoming postmenopausal , unless permanently sterile.  
• A postmenopausal state is defined as when a  woman has experienced no menses for 
12 consecutive months without an alternative medical cause.  
• A high follicle -stimulating hormone (FSH) level in the postmenopausal range should b e 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT ).  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non -estrogen hormonal highly effective contraception methods if they wish to continue 
their HR T during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrollment.  
Permanent sterilization methods include:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophor ectomy  
• For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), Investigator 
discretion should be applied to determining study entry eligibility . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 75 Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.  
• If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be con firmed before first administration  of study intervention, additional evaluation 
should be considered.  
10.4.2  Contraception guidance   
Female participants of childbearing potential are e ligible to participate if they agree to use 
a highly effective method of contraception consistently and correctly as described below  in 
Table  7. 
Table  7 - Highly effective contraceptive methods   
Highly effective contraceptive methods t hat are user dependenta 
Failure rate of <1% per year when used consistently and correctly  
• Combined (estrogen - and progestogen -containing) hormonal  contraception associated with inhibition of ovulation  
- (oral, intravaginal , or transdermal ) 
• Progestogen -only hormone contraception associated with inhibition of ovulation  
- (oral or injectable ) 
Highly effective methods that are user independenta 
• Implantable progestogen -only hormonal contraception associated with inhibition of ovulation  
- Intrauterine device (IUD)  
- Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Essure procedure  
Vasectomized partner  
Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not and less than 1 year after 
vasectomy, additional highly effective method of contraception should be used. Spermatogenesis cycle is approximately 
90 days.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during 
the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the p referred and usual lifestyle of the participant.  
NOTES:  
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local reg ulations 
regarding the use of contraceptive methods for participants participating in clinical studies.  
      
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 76 10.5 APPENDIX 5: GENETICS   
Future  use/analysis of  DNA  
• Genetic variation may impact a participant’s response to study intervention , susceptibility 
to, and severity and progression of disease. Variable response to study intervention  may be 
due to genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology ; and/or molecular subtype of 
the disease being treated. Therefore, where local regulations and IRB/IEC allow, a blood 
sample will be collected for  possible future  DNA analysis from consenting participants.  
• While there are no planned DNA analyses in this s tudy, future research related to the 
complement pathway, ITP, and related diseases  may use DNA samples collected from this 
study, if the participant provides consent . They may also be used to develop tests/assays 
including diagnostic tests related to  compl ement pathway inhibitors and ITP. Genetic 
research may consist of the analysis of one or more candidate genes or the analysis of 
genetic markers throughout the genome or analysis of the entire genome  (as appropriate).  
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to BIVV020 or study interventions  of this class to understand 
study disease or related conditions.  
• The Sponsor  will store the DNA samples in a secur e storage space with adequate measures 
to protect confidentiality.  
• The samples will be retained while research on BIVV020 continues but no longer than 
15 years or other period as per local requirements.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 77 10.6 APPENDIX 6: SAFETY: SUGGESTED AC TIONS AND FOLLOW -UP ASSESSMENTS   
 
Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Section  10.3.1  is met.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 79  
Increase in serum creatinine is to be recorded as an AE only if at least 1  of the criteria listed in the 
general guidelines for reporting AEs in Section  10.3.1  is met . 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 80 10.7 APPENDIX 7: AES,  ADES,  SAES, SADES, USADES  AND DEVICE DEFICIEN CIES: 
DEFINITIONS AND PROC EDURES FOR RECORDING , EVALUATING, FOLLOW -UP, 
AND REPORTING IN MED ICAL DEVICE STUDIES   
Not applicable.  
10.8 APPENDI X 8: COUNTRY -SPECIFIC REQ UIREMENTS   
Not applicable.  
10.9 APPENDIX 9: CONTINGE NCY MEASURES FOR A R EGIONAL OR NATIONAL 
EMERGENCY THAT IS DE CLARED BY A GOVERNME NTAL AGENCY   
The following contingencies may be implemented for the duration of the emergency (after 
Sponsor agreement is obtained).  
Study intervention  
If a participant has to stop BIVV020 due to a re gional or national emergency (eg, COVID -19), 
re-initiation of the study intervention can only occur once the Investigator has determined, 
according to his/her best judgement, that 1) BIVV020 did not contribute to the occurrence of the 
concerned adverse event and 2) the selection criteria for the study a re still met (refer to Section  5). 
Re-initiation of the study intervention will be done under close and appropriat e clinical/and or 
laboratory monitoring and in consultation with the Sponsor.  
Study assessments and procedures  
During  the emergency, if the site will be unable to adequately follow protocol mandated 
procedures, alternative treatment outside the clinical tr ial should be proposed, and 
screening/enrollment/administration of study intervention may be temporarily delayed.  
Attempts should be made to perform all assessments in accordance with the approved protocol to 
the extent possible. In case this is not possi ble due to a temporary disruption caused by an 
emergency, focus should be given to assessments necessary to ensure the safety of participants 
and those important to preserving the main scientific value of the study.  
Procedures to be considered in the event  of a regional or national emergency declared by a 
governmental agency:  
• If onsite visits are not possible, remote visits (eg, with home nurses, home health vendor, 
etc) may be planned for the collection of possible safety and/or efficacy data.  
• If onsite vi sits are not possible, visit windows may be extended for assessment of safety 
and/or efficacy data that cannot be obtained remotely.  
• Use of local clinic or laboratory locations may be allowed when central labs cannot be 
performed due to a government decla red national emergency.  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 81 Statistical analyses  
The impact of the regional or national emergency declared by a governmental agency  on study 
conduct will be summarized (eg, study discontinuation or discontinuation/delay/omission of the 
intervention due to the emergency). Any additional analyses and methods required to evaluate the 
impact on efficacy (eg, missing data due to the emergency)  and safety will be detailed in the SAP.  
Informed consent  
For a regional or national emergency declared by a governmental age ncy, contingency procedures 
may be implemented for the duration of the emergency. The participant or their legally authorized 
representative should be verbally informed prior to initiating any changes that are to be 
implemented for the duration of the emer gency (eg , study visit delays/treatment extension, use of 
local labs).  
10.10  APPENDIX 1 0: ABBREVIATIONS   
 
ADA:  antidrug antibodies  
AE: adverse event  
AESI : adverse event of special interest  
ALT:  alanine aminotransferase  
C1s: complement component 1, s subcomponent  
CAD:  cold agglutinin disease  
COVID -19: coronavirus disease 2019  
  
CRF:  case report form  
CTCAE:  Common Terminology Criteria for Adverse Events  
DTP:  direct to patient  
ECG:  electrocardiogram  
eCRF:  electronic case report form  
EOS:  end of the study  
FIH:  first-in-human  
GCP:  Good Clinical Practice  
GDPR:  Gener al Data Protection Regulation  
GLP:  Good Laboratory Practice  
HCV:  hepatitis C virus  
HIV:  human immunodeficiency virus  
HRT:  hormonal replacement therapy  
IB: investigator's brochure  
ICH:  International Council for Harmonisation  
IEC:  Independent Ethics Committe e 
IMP:  investigational medicinal product  
IRB:  institutional review board  
ITP: immune thrombocytopenia  
IV: intravenous  
VV-CLIN-0592756 4.0

Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 82 IVIg:  intravenous immunoglobulin  
PCSA:  potentially clinically significant abnormality  
PCV13 : 13-valent pneumococcal  
PD: pharmacodynamics  
PK: pharmacokinetics  
PPSV23 : 23-valent pneumococcal  
PT: prothrombin time  
SAE:  serious adverse events  
SAP:  statistical analysis plan  
SARS -CoV -2: serious acute respiratory syndrome coronavirus 2  
SC: subcutaneous  
SLE:  systemic lupus erythematosus  
SoA:  schedule  of activities  
SOC:  system organ class  
SUSAR:  suspected unexpected serious adverse reactions  
TEAE:  treatment -emergent adverse event  
TESAE:  treatment -emergent serious adverse event  
ULN:  upper limit of normal  
WBC : white blodd cells  
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 83 10.11  APPENDIX 1 1: PROTOCO L AMENDMENT HISTORY   
This is the third  amendment of the protocol. Changes to the protocol for amended protocol 0 3 are 
summarized before the Table of Contents.   Changes to the pr otocol for amended protocols 01 and 
02 are summarized in this section.  
Amended protocol 02 (10 December 2020)  
This amended protocol 02 (Amendment 02) is considered to be substantial  based on the criteria 
set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of 
the European Union.  
OVERALL RATIONALE FOR THE AMENDMENT   
Changes in the protocol have been implemented to address requests received f rom the US Food 
and Drug Administration as well as additional corrections and clarifications.  
PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Section # and Name  Description of Change  Brief Rationale  
1.3 Schedule of activities  Pre-dose weight added on Day 1  Weight needed for loading dose  
1.3 Schedule of activities, 
footnote g; 
8.2.6  Vaccinations against 
encapsulated bacteria  Titers may not be used in lieu of documentation of prior 
vaccination  Clear titer cutoffs associated with 
protection do not exist for most of t he 
required vaccines  
5.1 Inclusion criteriion I03  For participants who have not previously received 
sutimlimab, one of their prior treatments must have 
been a thrombopoietin receptor agonist  US FDA request  
6.8 Concomitant therapy  Clarification that vaccinations, such as the seasonal 
influezna vaccine, are permitted during the study  Clarification  
6.8.1 Rescue medicine  Clarification that a dose increase in a concomitant ITP 
medication is considered rescue therapy  Clarification  
8.2.4.1 Additional test ing in 
case of 
hypersensitivity/allergic 
reaction  Clarification of testing to be performed in case of 
hypersensitivity/allergic reaction  Some of the lab tests listed in the 
prior version were difficult to perform 
and of unclear utility  
8.3.1 Time period and 
frequency for collecting AE 
and SAE information  Additional information for participants transitioning from 
study TDR16218  For these participants there are 
additional requirements and 
considerations for AE/SAE reporting  
10.1.9 Study and site start 
and closure  Addition of a dosing and enrollment hold for toxicity  US FDA request  
10.2 Appendix 2: Clinical 
Laboratory Tests  Thrombopoietin removed from clinical chemistry panel  Test not essential for study and 
cannot be performed through the 
central lab  
Throughout  Additional clarifications and corrections to typography 
and formatting  Clarification and consistency with 
document standards  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 84 Amended protocol 01 (08 December 2020)  
Changes for amended protocol 01  (08 December 2020)  were  considered to be substantial based on 
the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the 
Council of the European Union.  
OVERALL RATIONALE FOR AMENDMENT 01  
Changes in protocol  amendment 01  were implemented to address requests received in a Voluntary 
Harmonisation Procedure communication.  
PROTOCOL AMENDMENT 01 SUMMARY OF CHANGES  
Section # and Name  Description of Change  Brief Rationale  
1.1 Synopsis, Overall design; 
1.3 Schedule of activities, footnote e; 
2.3 Benefit/Risk assessment; 4.1 Overall 
design; 4.2  Scientific rationale for study 
design  Addition of a maximum duration of treatment of 
104 weeks per participant, and also noted long-term 
safety profile for sutimlimab, another compound 
with a similar mechanism of action.  Added limit as a safety 
measure, and added further 
information to support 
likelihood of long -term 
safety  
1.1 Synopsis, Overall design; 
4.1 Overall design, 6.1.2  Subcutaneous 
dose administration  Specified that participants should be observed for 
30 minutes after IMP administration for the first 
6 SC administrations  Additional safety monitoring  
1.1 Synopsis, Data Monitoring/Other 
committee;  
10.1.5 Review Com mittees  Added mention of Data Monitoring Committee to 
synopsis, renamed “Data Monitoring Committee” 
subheading as “Study Monitoring Committee,” and 
added a brief description of the Data Monitoring 
Committee, which will include at least 
2 investigators part icipating in the study  Increased safety monitoring  
1.3 Schedule of activities; 5.1 Inclusion 
critierion I05  Male and female participants are now required to 
continue contraception until 52 weeks after the last 
dose of BIVV020. A urine pregnancy test was 
added to the End of Study visit for women of child -
bearing potential.  Required contraception 
extended due to the 
prolonged half -life of 
BIVV020  
6.1 Study interventions administered 
(new subsections 6.1.2 and 6.1.3  Additional details for IMP administration  added  Health authority request  
6.2 Preparation/handling/  
storage/accountability  Added statement referring to the Pharmacy Manual 
for procedure details  Clarification  
6.8 Concomitant therapy  Clarification that thrombopoietin agonists may be 
restarted by the Investigator after BIVV020 
administration if a participant has an insufficient 
response to BIVV020  Clarification  
new section added:  
7.1.5 Thrombocytosis; subsequent 
subheadings renumbered  A new section was added to specify that BIVV020 
should be disco ntinued if platelet counts rise above 
450 x 109/L Added guidance for 
thrombocytosis  
10.1.1 Regulatory and ethical 
considerations  Clarification that the Declaration of Helsinki 
guidelines referenced are the most recent 
guidelines from 2013  Clarification  
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 85 Section # and Name  Description of Change  Brief Rationale  
10.4.2 Contraceptive guidance  Double -barrier contraception removed as a highly 
effective contraceptive method  Double barrier contraception 
is not considered to be 
highly effective as per the 
Clinical Trial Facilitation 
Group  
 
VV-CLIN-0592756 4.0
Amended Clinical Trial Protocol 03  
BIVV020 -PDY16894  25-Jan-2021  
Version number: 1 
 
Property of the Sanofi group - strictly confidential  Page 86 11 REFERENCES   
1. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227 -35. 
2. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets 
correlates with a decrease in circulating immature platelets in patients with immune 
thrombocytopenic purpura. Br J Haematol. 2010;148:638 -45. 
3. Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, et al. Autoantibody -mediated 
complement activation on platelets is a common finding in patients with immune 
thrombocytopenic pu rpura (ITP). Eur J Haematol. 2012;88:167 -74. 
4. Peerschke EI, Panicker S, Bussel J. Classical complement pathway activation in immune 
thrombocytopenia purpura: inhibition by a novel C1s inhibi tor. Br J Haematol. 2016;173:942 -
5. 
5. Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 
2018;181:320 -30. 
6. Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A. Complement evasion strategies of 
viruses: An overview. Front Microbiol. 2017;8:1117.  
7. Java A, Apicelli AJ, Liszewski MK, Reilly AC,  Atkinson JP, Kim AHJ, et al. The 
complement system in COVID -19: friend and foe? JCI Insight. 2020;5(15):140711.  
 
 
VV-CLIN-0592756 4.0
Signature Page for VV-CLIN-0592756 v4.0
pdy16894-16-1-1-amended-protocol03
Approve & eSign
Approve & eSign
ClinicalVV-CLIN-0592756 4.0
